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Abstract 
 
 
The regulation of intracellular signaling is critical to the ability of a T cell to develop, 
survive, and function in an immune response. In this work, we examined the effect of 
T cell-specific deletion of the Ras GTPase-activating protein (RasGAP) 
neurofibromin (NF1) on T cell development and function. We have determined that 
NF1 has a non-redundant role in T cell development in the thymus as well as in 
peripheral T cell homeostasis. NF1-deficient naïve CD8+ T cells express higher 
amounts of the effector cytokine interferon- (IFN-) and the transcription factor 
Eomesodermin, and this is likely the reason for the ability of T cell-specific 
neurofibromin-deficient mice to respond more efficiently to Listeria monocytogenes 
infection in vivo.  
 
We have also determined that the cytokine IL-4 is an inducer of IFN- expression in 
wild-type CD8+ T cells. IL-4 directly induces transcription at the ifng locus, which is 
augmented by concomitant T cell antigen-receptor (TCR) stimulation, and is likely 
due to IL-4-mediated upregulation of the transcription factors Eomesodermin and T-
bet. The effects of IL-4 on IFN- expression in CD8+ T cells are mediated by Ras-
ERK and PI3K signaling, with dependence on STAT6 activation when the TCR is 
activated concomitantly with the IL-4 receptor. 
xii 
 
Finally, we show that the induced systemic loss of both NF1 and the related RasGAP 
RASA1 in adult mice promotes the development of T cell lymphoma. Lymphoma 
cells were found to populate all hematopoietic and were CD4
+
CD8
+ 
CD25
+
TCR
-
 cells 
of thymic origin. Tumor cells were also found to possess activating mutations in 
Notch1, a hallmark of both human and murine T cell acute lymphoblastic 
lymphoma/leukemia (T-ALL), in all but one instance of disease. Altogether, this 
work demonstrates the importance of regulation of signal transduction pathways in 
normal T cell function. 
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Chapter 1 
 
Introduction 
 
 
 
In the following work, I have sought a clear understanding of the molecular 
mechanisms that govern T cell development and function. Such knowledge that is 
acquired in basic research can be applied to translational and clinical research. 
Ultimately, elucidation of as-yet unknown causes behind phenotypically well-
characterized human diseases and disorders and better treatments for such diseases 
may result from such research. 
 
 
1.1 The small GTPase Ras 
 
Ras signaling and function 
The small GTPase Ras, a 21 kDa protein, is a key component of intracellular 
pathways in all cells that transmit signals from the extracellular matrix to the nucleus 
(2). The activation and subsequent tyrosine phosphorylation of a cell surface receptor, 
such as a cytokine, growth factor, or antigen receptor, initiates a signaling cascade 
that results in the exchange of Ras-bound GDP for cytosolic GTP. This exchange 
induces a conformational change in the tertiary protein structure of Ras and renders 
Ras active (5). Once active, Ras further transmits signals that promote cell growth, 
proliferation, and survival (6). Activated Ras transmits signals primarily through the 
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mitogen-activated protein kinase (MAPK) and phosphoinoside 3- kinase (PI3K) 
pathways (6). Ras-GTP binds Raf-1, a serine-threonine kinase that functions as a 
MAPK kinase kinase, which in turn phosphorylates the MAPK kinase MEK. MEK 
activates ERK1/2 by phosphorylation of tyrosine and threonine residues (7, 8). Upon 
activation, ERK phosphorylates and activates transcription factors including NF-AT, 
Elk, and c-fos, which translocate to the nucleus (8). Ras activates PI3K by acting 
directly on the p110 kDa subunit (9). Akt is activated downstream of PI3K and acts to 
promote cell growth and proliferation through mTOR and other cell cycle-related 
proteins as well as Bcl-2-mediated survival (10) (Fig. 1). 
 
 
Ras isoforms 
Ras is expressed in three isoforms: K-Ras, N-Ras and H-Ras, which are understood to 
localize to distinct locations within the cell and to signal differently through 
downstream effectors (11). K-Ras, for example, is reported to more strongly promote 
Raf activation and thus to promote ERK activation; H-Ras is reported to 
preferentially promote PI3K activation (12, 13). Studies of Ras isoform deletion and 
embryonic lethality in mice using null alleles showed that K-Ras was the only 
isoform required for embryonic development, although its activation must be tightly 
controlled, as expression of constitutively active K-Ras also results in embryonic 
lethality (14, 15). The importance of K-Ras is underscored by experiments in which 
double-deletion of H-Ras and N-Ras failed to result in embryonic lethality (14, 16, 
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17). N-Ras-deficient mice were found to have abnormal thymocyte development and 
attenuated T cell activation in response to viral infection (18).  
 
 
Oncogenic Ras signaling 
Approximately one-third of human tumors have been reported as consequent to 
dysregulated Ras signaling (19), due either to the loss of the ability of Ras to function 
as a GTPase or inability to bind to negative regulatory proteins due to Ras mutations 
(20). Given the role of Ras as a promoter of cell growth, proliferation and 
differentiation, it is understandable that unchecked Ras activity could lead to 
malignant transformation of a cell. Although Ras is expressed in three isoforms, K-
Ras is the most commonly mutated isoform found in human tumors, occurring in 
approximately 20% of human tumors, or nearly two-thirds of all Ras-directed tumors 
(21). In hematopoietic cells, N-Ras mutations are most common (22), but K-Ras 
mutations are widely reported in T-cell acute lymphoblastic leukemia (T-ALL) (20, 
23). 
 
 
Regulation of Ras signaling 
Regulation of Ras activity is important to maintain tissue homeostasis and cellular 
effector function as well as to prevent unchecked growth and survival. Ras is 
positively regulated by the Ras guanine-nucleotide exchange factors (RasGEFs) (24).
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Although several RasGEFs are known to be expressed in humans and mice, the best-
studied RasGEF family member is SOS, which is highly conserved across species (2). 
Upon activation, SOS is recruited to the plasma membrane by the adapter protein 
Grb2, which docks to phosphorylated tyrosine residues on activated receptors or 
intermediate scaffolding proteins (2, 25). SOS is then able to interact with Ras and 
facilitate the release of bound GDP. Although RasGEFs do not directly promote the 
binding of GTP over GDP, the high ratio of free GTP to GDP in the cytosol increases 
the likelihood that GTP will fill the empty Ras binding pocket (24). Negative 
regulation of Ras activity is controlled by a family of catalytic proteins known as the 
Ras-GTPase activating proteins. 
 
 
Figure 1. Ras signaling in the cell. (2) 
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Ras GTPase-activating proteins 
Within the cell, the Ras GTPase-activating proteins (RasGAPs) are responsible for 
the negative regulation of Ras activity. The RasGAP family is comprised of multiple 
members, all of which possess a catalytic GAP-related domain (26). The proteins are 
further categorized by the possession of other modular binding domains that facilitate 
protein-protein interactions as well as localization within the cell (5, 26-28). 
RasGAPs are differentially expressed in tissues and during developmental stages, 
which has presented challenges to loss-of-function studies involving null or 
conditional-null allele mutations in vivo due either to embryonic lethality or to 
redundancy of RasGAP function due to overlapping expression patterns (29-32).  
 
RasGAPs exert their effects on Ras via the above-mentioned GAP domain. This 
domain permits the binding of RasGAP to GTP-bound Ras, at which point the 
RasGAP facilitates the cleavage of the -phosphate from the bound GTP, promoting 
its release as inorganic phosphate and returning Ras to its inactive GDP-bound state 
(33). In the two best-studied RasGAPs, RAS p21 protein activator 1 (RASA1) and 
neurofibromin (NF1), an arginine-finger motif was determined to act as a key 
catalytic residue within the GAP domain, where it acts to stabilize both the position 
of key residues on Ras itself and the charge distributions within the catalytic reaction 
(34, 35), as well as catalyze the hydrolysis of GTP to GDP and Pi (36).  
 
Research into the requirements for individual RasGAPs within a cell is complicated 
by the understanding that the importance of individual RasGAPs may differ with the 
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activity levels of a cell. For example, NF1 is thought to act as a basal regulator of Ras 
due to its much higher binding affinity for Ras-GTP, while its fellow RasGAP 
RASA1, which has a lower RasGTP-binding affinity, is thought to regulate Ras in 
activated cells, when Ras-GTP levels are at a higher concentration within the cell (37, 
38). RasGAPs are also believed to differentially regulate different Ras isoforms, 
which localize differently within the cell and thus affect signal transduction patterns 
(11, 26). 
 
RASA1 
RASA1 is a 120 kDa protein comprised of a number of modular binding domains as 
well as the catalytic GAP domain (39). In addition, RASA1 contains two SH2 
domains, a SH3 domain, pleckstrin-homology (PH) domain, and a calcium-dependent 
lipid-binding (C2) domain (5, 26, 39). These domains support interactions with other 
signaling or scaffolding proteins, leading to the regulation of Ras activity and related 
downstream events (40, 41). RASA1 is also known to interact with p190 RhoGAP 
through its SH2 domains, thus impacting on pathways regulated by Rho GTPase, 
such as cell migration (42, 43).  
 
In humans, a mutated allele of Rasa1, which codes for the protein RASA1, is known 
as a causative agent of the disorders capillary malformation-arteriovenous 
malformation (CM-AVM), an autosomal-dominant disorder characterized by defects 
in blood vasculature development (44). In mice, full deletion of RASA1 was found to 
induce embryonic lethality due to defects in cardiovascular development (29), 
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underscoring the critical role of RasGAPs across species. Induced systemic deletion 
of RASA1 in adult mice led to hyperplasia of the lymphatic vasculature (45). RASA1 
inactivation-related abnormalities in the blood vasculature of adult mice were 
observed, although only in the context of tumor-related angiogenesis (46), an 
example that further underscores the differential requirements for RasGAPs in 
tissues.  
 
 
Neurofibromin  
Neurofibromin (NF1) is a 250 kDa protein comprised of the requisite GAP domain as 
well as a tandem Sec14 and PH-like domain, which is believed to bind to 
glycerophospholipids, indicating its potential importance in directing NF1 to plasma 
membranes (47, 48). Although NF1 is a large protein, no other functional domains 
have been identified to date, although the frequency of reported non-truncating 
mutations throughout the length of NF1 in humans with NF1-related disease indicates 
that other functional domains have yet to be identified (49). 
 
Although comparatively little is known about the structure of NF1, it is well known in 
the context of human disease. Mutations in the gene Nf1 are responsible for the 
disorder neurofibromatosis type 1, an autosomal-dominant disorder that affects 
approximately 1 in 3500 people (50, 51). Neurofibromatosis type one is classically 
accompanied by the development of peripheral nerve sheath tumors, or 
neurofibromas, which are frequently benign. Other presentations include the 
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appearance of café au lait macules on the skin, optic gliomas, cognitive deficiencies, 
and an increased susceptibility toward leukemias of the myeloid cell compartments 
(52-54). Similar phenotypes have been observed in mice with tissue-specific 
conditional deletions of NF1, indicating that the roles of NF1 are well-conserved 
between species. 
 
Ras-related disorders in humans 
A number of human disorders are related to dysregulation of Ras signaling. These 
„RASopathies‟ can result from gain- or loss-of-function mutations in Ras itself as 
well as in proteins that regulate Ras and its downstream effectors (22). Human 
disorders that result from such mutations include Noonan, LEOPARD, Costello, and 
cardio-facio-cutaneous syndromes, all of which are characterized by developmental 
abnormalities in the musculoskeletal, cardiovascular and neural systems (55, 56). 
Some overlap of phenotype has been observed between Ras- and RasGAP-related 
disorders. In studies of interferon-inducible gene targeting, expression of 
constitutively active KRas was shown to induce the development of 
myeloproliferative disorder (57), similar to that which is observed in both NF1-
deficient mice and humans with loss-of-function mutations in nf1.  
 
1.2 Signal transduction pathways in T cells 
 
TCR-mediated signaling 
Interaction of the T cell antigen receptor (TCR) with its cognate antigen-MHC 
complex sets in motion a number of downstream signaling cascades (Fig. 2). In the 
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instance of such an interaction, the coreceptors CD4 and CD8 localize to the 
immunological synapse with the TCR. CD4 and CD8 interact with MHC class II and 
class I molecules, respectively, and in doing so draw the Src-family kinase Lck, 
which is associated with the cytoplasmic tails of CD4 and CD8, close to the TCR-
associated CD3 complex. Lck, much of which is constitutively activated in 
thymocytes, is then able to phosphorylate the CD3 chains, permitting the binding 
and phosphorylation of ZAP-70 (58, 59). Activated ZAP-70 then phosphorylates 
multiple tyrosines on the membrane-tethered scaffolding protein LAT, which 
facilitates the branching of proximal TCR signaling into several distal signaling 
pathways through its role as a docking site for several SH2-domain-containing 
proteins (60).  
 
LAT phosphorylation promotes activation of the small GTPase Ras in two ways. 
First, the protein PLC- binds to LAT, which facilitates the ability of PLC- to cleave 
phosphotidylinositol-4,5-bisphosphate (PI(4,5)P2)) to diacylglycerol (DAG) and 
inositol trisphosphate (IP3) (3, 61). DAG localizes to the plasma membrane, where it 
is able to attract and bind the RasGEF RasGRP1 (62). Second, the adaptor protein 
Grb2 also binds to LAT and in so doing is able to bind and activate the RasGEF Sos 
(61). The differential localization of these activated RasGEFs within the T cell is 
thought to contribute to differential Ras signaling in response to the strength of TCR 
interaction with the cognate antigen-MHC complex (62, 63). Following activation by 
RasGRP1 and Sos, Ras exerts its effects on T cell development, growth and 
differentiation primarily through the Raf-MEK-ERK and PI3K pathways (3, 64, 65). 
10 
 
 
 
 
 
T cells also receive signal through costimulatory receptors. Concomitant signals 
through these receptors can provide „signal 2‟ to induce full activation of T cells 
when „signal 1‟ is received through the TCR. The requirement for a second signal 
prevents inappropriate activation of T cells, i.e. activation of T cells in response to 
self-antigen (66, 67). One of the best-studied coreceptors expressed on T cells is 
CD28. Its ligand is CD80/CD86, expressed on activated dendritic cells, and binding 
of CD28 to its ligand occurs when the TCR is in contact with its cognate antigen-
MHC complex on the dendritic cell (68). Signal transduction through CD28 further 
enhances PI3K activation in T cells (69). 
 
 
Figure 2. Activation of Ras downstream of the TCR. (3) 
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Common -chain cytokines in homeostasis and effector function  
The common-chain (c) family designates cytokines that recognize a group of 
receptor complexes, all of which include the c as one receptor subunit. IL-2, IL-4, 
IL-7, IL-9, IL-15, and IL-21 belong to the c family, and all exert effects on T cells to 
promote development, survival, and effector function (70). All of these cytokines 
signal through the c-associated transcription factors signal transducers and activators 
of transcription (STAT) 5a/b, which are activated by the receptor-associated Janus 
kinase 3 (JAK3) to the extent that deletion of STAT5 proteins in adult mice 
significantly impairs normal T cell development and function (71, 72). Individual 
effects of each c cytokine are largely mediated by signal transduction events, both 
STAT-associated and otherwise, downstream of the other subunit or subunits that 
comprise the individual cytokine receptors (70, 73).  
c cytokines exert their affects on T cells in a number of ways. IL-7 is well-known as 
a peripheral survival factor for T cells (70, 74, 75). IL-15 is thought to promote 
homeostasis of central memory T cells, although it has also been shown to be 
required for the maintenance of naive CD8
+
 T cell homeostasis (74, 76). IL-21 has 
been shown to promote the survival of naïve CD8
+
 T cells in mice and to act with IL-
7 and IL-15 to promote both naïve and memory CD8
+
 T cell proliferation and effector 
functions in vitro (77). IL-4 is a prominent inducer in the differentiation of CD4
+
 T 
cells to the type 2 helper T cell (Th) lineage and is a hallmark effector cytokine of 
Th2 cells (70). IL-9 is also considered to be an effector cytokine of the Th2 and Th 
lineage (70).  
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IL-2 is well known as a growth factor for T cells, although IL-2-deficient mice have 
been found to have dysregulated T cell proliferation accompanied by autoimmune 
disease (70, 78, 79). This is due to the role of IL-2 in the maintenance of peripheral 
tolerance and T cell homeostasis by promoting the survival of regulatory T cells as 
well as by regulating the apoptosis of effector T cells through activation-induced cell 
death (AICD) following the resolution of the immune response to infection (70, 79, 
80).  IL-2 is also known to promote the differentiation of CD4
+
 T cells to the T helper 
cell type 2 (Th2) lineage (81).  
 
Ras signaling in T cells 
Ras activity has been shown to be a key mediator of signal transduction downstream 
of the TCR, with both developmental and functional consequences (82). Expression 
of constitutively active Ras in T cells permitted the reversal of induced anergy, while 
expression of active NRas resulted in the development of autoimmune 
lymphoproliferative syndrome (83, 84). Further, expression of a constitutively active 
form of ERK, to mimic continuous signaling through the Ras-ERK pathway, resulted 
in the loss of peripheral T cells (85). Although the factors involved in positive 
regulation of Ras in T cells are well understood, less is known about the role of 
RasGAPs in the negative regulation of Ras signaling in T cells. The RasGAP family 
members RASA1, NF1, and RASAL3 are known to be expressed in thymocytes and 
T cells, and this overlapping expression is likely to result in some redundancy of 
function. However, it is becoming clear that the individual RasGAPs have non-
redundant roles in the T cell compartment. NF1 has been reported to regulate 
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thymocyte and T cell homeostasis and activation-induced proliferation (86). More 
recently, RASA1 has been reported to regulate thymocyte positive selection as well 
as peripheral T cell survival (32). However, much remains to be determined regarding 
the functions of these negative regulators of Ras signaling in T cells. 
 
 
1.3. Thymocyte development 
 
The primary organ for T cell development is the thymus. In the event of inability to 
develop a thymus, as seen in nude mice or humans with DiGeorge‟s syndrome, T cell 
production is inhibited and the host is severely immunocompromised (87, 88). The 
thymus is comprised of several lobes, each containing both cortical and medullary 
zones. Developing thymocytes progress from the cortex to the medulla, encountering 
thymic  epithelial cells throughout the process. 
 
Early thymocyte development 
The thymic cortex is seeded by early thymic progenitors (ETPs), descendants of 
hematopoietic stem cells in the bone marrow (89) (Fig. 3). At this early stage, ETPs 
are also known as double-negative (DN) thymocytes, due to their lack of the T cell 
co-receptors CD4 and CD8, as well as lack of expression of the T cell-antigen 
receptor (TCR). DN thymocytes can be further analyzed to belong to four 
developmental stages: DN1, characterized by high expression of CD44; DN2, 
characterized by continued expression of CD44 as well as high expression of 
CD25/IL-2 receptor  (IL-2R); DN3, low expression of CD44 and continued high 
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expression of CD25; and DN4, low expression of both CD44 and CD25 (90). The 
downregulation of CD44 correlates not only with the downregulation of the early 
thymocyte marker c-kit, but also with the rearrangement of the TCR locus at the 
transition from DN2 to DN3 (90). The pre-TCR is also expressed in DN3 and 
dimerizes with the newly expressed TCR. The resulting pre-TCR must be able to 
conduct signal to the nucleus via interaction with the CD3 complex (91, 92); failure 
to properly signal through the pre-TCR results in a developmental block at DN3 (93). 
Thymocytes that express functional TCR subunits are able to transition to DN4, 
characterized by downregulation of CD25 expression (94).  
 
Thymocyte selection 
Transition to the double-positive (DP) stage of thymocyte development is 
characterized by expression of CD4 and CD8.  Following surface expression of the 
TCR, DP thymocytes undergo the process of thymocyte selection, in which the 
newly formed TCR is tested for appropriate signal transduction. This process is 
critical for the production of a T cell repertoire that can respond to survival signals 
from MHC molecules bound to self-antigen peptides as well as foreign peptides 
within the context of self-MHC. It is also essential to prevent the development of 
autoimmune disorders, many of which are characterized by strongly self-reactive T 
cells. Under the widely accepted “strength of signal” model, DP thymocytes that 
respond to self-antigen are selected for further maturation (95). „Positive selection‟ 
distinguishes thymocytes that can respond to self-antigen, as presented by cortical 
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thymic epithelial cells, strongly enough to reach the minimum signal threshold for 
survival (96). The majority of DP thymocytes (approximately 90%) are unable to 
reach this minimum threshold and die by neglect (4). Of the remaining cells, those 
that respond very strongly to self-antigen, expressed by medullary thymic epithelial 
cells under the control of the transcription factor Aire, are deleted in a process called 
„negative selection‟ (97). Surviving thymocytes respond to peptide in the context of 
either MHC class I or class II and downregulate surface expression of CD4 or CD8 
accordingly (4). 
 
 
Figure 3. Thymocyte development. (4) 
16 
 
Ras signaling in T cell development 
The Ras signaling pathway is understood to play a critical role in thymic selection. 
Ras-ERK signaling is known to be required for the transition from the DN to DP 
stages of thymocyte development (98, 99). ERK1/2 phosphorylation downstream of 
Ras activation has been shown to have a role in the regulation of positive selection 
(99, 100). Recently, the protein Themis has been discovered to be critical for positive 
selection through its binding of Grb2, an adaptor protein that binds and activates the 
RasGEF Sos (101, 102).  Expression of a constitutively active form of ERK2 in 
murine thymocytes resulted in preferential transition of DP thymocytes to the CD4 SP 
lineage (85). However, the mechanisms by which Ras is negatively regulated in 
thymocytes are still largely unclear.  
 
1.4. T cells in the periphery 
 
Peripheral survival and homeostasis of naïve T cells 
Fully mature T cells, upon exit from the thymus, circulate through the bloodstream. 
Peripheral T cells circulate through the lymphatic vasculature and lymph nodes for 
two reasons: first, circulating T cells receive survival signals from stromal cells in the 
lymph nodes; second, in the event of an infection, circulation increases the likelihood 
that an antigen-specific T cell will encounter its cognate antigen in a draining lymph 
node. Maintenance of the peripheral T cell compartment, or homeostasis, is critical to 
the ability of a host to efficiently respond to pathogens and to prevent autoimmune 
reactions from highly self-reactive T cells that escaped negative selection.  
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Naïve T cells continuously receive survival signals during circulation. Efficient 
thymic selection should ensure that all peripheral T cells can respond to self-MHC at 
a basal level while deleting cells that respond strongly enough to increase the 
likelihood of autoimmune responses (103). Thus, T cells are able to continuously 
sample self-MHC complexes, allowing them to receive low-level TCR activation that 
promotes survival (62, 74, 103). Survival signals are also transmitted through the IL-7 
receptor (IL-7R), expressed on resting T cells, which is activated in response to IL-7 
that is produced by epithelial cells and fibroblasts (70). Beyond mechanisms that 
promote survival, T cells maintain peripheral homeostasis through carefully regulated 
homeostatic proliferation, in which T cells in lymphopenic hosts expand to fill an 
underpopulated niche. The mechanisms behind lymphopenia-induced proliferation 
are not entirely understood. IL-7 is believed to play a role, as IL-7- or IL-7Ra-
deficient mice are chronically lymphopenic while overexpression of IL-7 can 
overcome intrinsic controls on the size of the T cell pool (74, 103, 104). 
 
T cell activation and effector functions 
Activated T cells comprise one arm of the host adaptive immune response against 
pathogens. In the event of pathogen infection, immature dendritic cells at the 
infection site mature into antigen presenting cells (APCs) as they take up antigenic 
material from the pathogen. APCs then travel to the draining lymph nodes, where 
they present antigen, costimulatory ligands, and effector cytokines to the circulating 
naïve and central memory T cells (105). T cells that encounter their cognate antigen-
MHC complex on a fully activated APC are induced to enter cell cycle to allow for 
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clonal expansion of a pathogen-specific T cell population, and are influenced toward 
differentiation to effector subsets by signals received from APCs (106). 
 
Helper T cells 
CD4
+
 effector T cells are also known as helper T (Th) cells, and „help‟  or direct 
effector cells primarily through the expression of effector cytokines, which influence 
the nature and scope of the response to pathogens. Type 1 or Th1 cells are 
characterized by the expression of the master transcription factor T-bet and the 
production of the inflammatory cytokine IFN-, which promotes the immune 
response to intracellular pathogens (107). Th2 cells express the transcription factor 
GATA-3 and are characterized by expression of the cytokine IL-4. These cells 
promote immune responses against extracellular pathogens by facilitating antigen-
specific B cell immunoglobulin class switching to produce opsonizing and 
neutralizing antibodies against such pathogens, as well as promoting the activation of 
the granulocytic eosinophils (108). Th17 cells express the transcription factor ROR-t 
and are characterized by production of the cytokine IL-17 (109). These cells are 
involved in the immune response against extracellular bacterial and fungal infections 
at the mucosal surface (106). Both Th1 and Th17 cells have also been implicated in 
autoimmune pathology (106). Although each Th subset expresses characteristic 
transcription factors and cytokines, differentiation to these subsets is no longer 
believed to be terminal, and the issue of Th cell plasticity is of much interest (106, 
110).  
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Cytotoxic T Lymphocytes  
CD8
+
 T cells also require encounters with their target antigen-MHC complex on 
APCs as well as costimulatory ligands and cytokines to become fully activated. 
However, CD8
+
 T cells also require assistance from CD4
+
 T cells in the form of 
enhancement of APC function, as well as from secreted cytokines such as IL-2 (111, 
112). CD8
+
 T cells enter cell cycle and begin to express the transcription factors T-bet 
and Eomesodermin (Eomes), which promote the expression of the effector cytokine 
IFN- (113). Interestingly, the differential expression of T-bet verses Eomes in CTLs 
has recently been shown to predict the capacity of a CTL to differentiate into a short-
lived effector CTL versus a memory CD8
+
 T cell, respectively (114-117). Cytotoxic 
proteins such as perforin and granzyme B are also expressed and are stored in lytic 
granules within the activated CD8
+
 T cell (111). These granules are released to kill 
infected cells which bear the target antigen-MHC complex for the activated CD8
+
 T 
cell (118). For this reason activated CD8
+ 
T cells are also known as cytotoxic T 
lymphocytes (CTLs). CTLs are critical in the adaptive immune response to viral 
infections as well as some intracellular bacterial pathogens (118).  
 
 
 
Memory T cell differentiation and homeostasis 
Following a successful adaptive immune response to a pathogen, the T cell 
compartment contracts to a fraction of its size at peak activation, in a process known 
as activation-induced cell death (AICD). Not only does this process allow for a return 
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to maintenance numbers of peripheral T cells, but it also reduces the number of clonal 
and potentially inflammatory effector T cells in the host (119). The cells that remain 
are those that have been targeted for differentiation to the memory T cell lineage. 
Maintenance of this memory T cell population is critical for the development of 
immune memory, in which the host is able to respond swiftly and effectively to a 
previously-encountered pathogen.  
 
Memory T cells can be divided into two major subsets. Effector memory T cells 
mainly reside within tissues, allowing for swift activation upon a secondary antigen 
encounter. Central memory T cells reside within the peripheral lymphoid organs and 
are reactivated upon antigen challenge in a much more rapid manner than are naïve 
cells, allowing for a faster response against infections (120). The latter subset is the 
target of effective T cell-mediated vaccination, as these cells are long-lived in the host 
(120). 
 
 
1.5 Scope of the thesis 
In this thesis, I have outlined three research projects, each of which investigates the 
effects of perturbations of signal transduction pathways on T cell development and 
function. In the first section, I investigated how the deletion of the RasGAP NF1 in 
the T cell compartment affects thymocyte development and peripheral T cell 
homeostasis. In the second section, I reported on the role of IL-4 in the promotion of 
CD8
+
 T cell effector function and provide an analysis of the signaling mechanisms by 
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which IL-4 exerts its effects on these cells. Finally, I described the first systemic 
concurrent deletion of the RasGAPs NF1 and RASA1 in adult mice, and demonstrate 
how this double deletion predisposes mice to the development of Notch1-mediated T 
cell lymphoma. This work has furthered our understanding of the regulation of Ras 
signaling in T cells as well as the molecular mechanisms that underlie CTL effector 
function. 
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Chapter 2 
 
 
The RasGAP neurofibromin as a regulator of T cell development 
 
2.1. Abstract 
 
Negative regulation of Ras activation downstream of the T cell antigen receptor is 
poorly understood. The RasGAP neurofibromin (NF1), which facilitates the 
inactivation of Ras, was conditionally deleted from the T cell compartment in mice at 
an early stage of thymocyte development. Heterozygous or total loss of NF1 resulted 
in a partial block of thymocyte development at the double-negative 3 (DN3) stage, 
and a partial block in the transition from the DP to CD8 single positive stage is 
evident in TCR-transgenic thymocytes. Mice with heterozygous or total loss of NF1 
had significantly fewer naïve peripheral T cells, particularly in the CD8
+
 subset, 
indicating a non-redundant role for NF1 in T cell homeostasis. NF1-deficient mice 
were more efficient in mounting a response to Listeria monocytogenes , clearance of 
which requires the activation of CD8
+
 T cells, in a five-day infection. Short-term in 
vitro stimulation of pan-T and CD8
+
 T cells demonstrated an increase in per-cell 
expression of interferon- and Eomesodermin in the naïve CD8+ T cell compartment 
in response to TCR stimulation. However, loss of NF1 did not affect Ras-ERK 
signaling in short-term in vitro cultures in either freshly isolated CD4
+
 or CD8
+
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T cells, nor was Ras-ERK signaling altered in previously activated T cell blasts. 
These findings suggest that the role of NF1 is non-redundant in thymocyte 
development and the maintenance of peripheral T cell homeostasis with moderate 
effects on T cell effector function. 
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2.2. Introduction 
The small GTPase Ras is a key modulator of signal transduction downstream of many 
cell surface receptors, including the T cell antigen receptor (TCR). Once the TCR is 
activated through binding to its cognate antigen in complex with the MHC on an 
APC, a signaling cascade is triggered that leads to the activation of Ras (121). Ras in 
turn promotes signaling through the MEK-ERK and PI3K pathways, leading to the 
translocation of the transcription factors AP-1, NF-B and NFAT to the nucleus and 
the transcription of key functional genes (3, 122-124). Ras signaling is critical not 
only for the development of T cells in the thymus, but also for the induction and 
maintenance of T cell effector functions in the periphery (125-127). The role of Ras 
in cell activation is significant in that its dysregulation is directly and positively 
associated with many types of tumors, including T cell-acute lymphoblastic leukemia 
(T-ALL) (128-130). Thus, it is important to understand the processes by which Ras is 
negatively regulated within the cell. 
  
Ras is negatively regulated by a family of proteins collectively known as the Ras 
GTPase-activating proteins (RasGAPs) (5). RasGAPs share a common GTPase-
activating protein (GAP) domain that facilitates the hydrolysis of the Ras-bound GTP 
to GDP and inorganic phosphate (33). The family members are distinguished from 
one another by the presence or absence of other modular protein domains, which 
assist in intracellular localization and scaffolding, as well as by tissue expression 
patterns (131). The high number of RasGAPs in the proteome yields the possibility of 
overlap of expression and function in a given cell type (27, 132). Although RasGAPs 
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are expressed in T cells, the specific functions of each are not yet well elucidated (3). 
Our lab has recently reported that mice bearing a T cell-specific deletion of the 
RasGAP family member RASA1 do not have grossly dysregulated T cell function, 
but that RASA1-deficiency does affect thymocyte development and peripheral T cell 
survival (32). 
 
The RasGAP neurofibromin (NF1) is named for its causative role in the human 
disorder neurofibromatosis type 1 (NF1) (133, 134). NF1 is an autosomal-dominant 
disorder, and many manifestations of this disorder result from a heterozygous 
mutation of the Nf1 gene (31, 135), as Nf1 is haploinsufficient in many tissues (136-
141). The disorder NF1 is classically characterized by the appearance of plexiform or 
dermal neurofibromas, café-au-lait spots and peripheral nerve sheath tumors that are 
malignant in a minority of cases (51, 142-145). Mutated forms of the protein NF1 
have also been implicated in murine and human cardiovascular disease, neural 
development, cognitive abnormalities, cell cycle maintenance, bone and muscular 
development (30, 31, 138, 146-153), and are associated with a greater risk of myeloid 
leukemia development (52-54, 154-156). 
 
NF1 is expressed in T cells, although a role for this protein in T cells has yet to be 
established. Nf1 mutations have been reported in a small number of patients with T-
cell acute lymphoblastic leukemia in the absence of clinical NF1 symptoms (157) and 
NF1 has been reported to modulate ERK activation downstream of N-Ras in a murine 
lymphoma model (158), indicating that NF1 may act as a tumor suppressor in the T 
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cell compartment. One previous report has indicated that although lymphocyte 
development appeared to be unaffected, RAG-deficient donor mice that had received 
NF1-deficent fetal liver cells showed proliferation of peripheral CD4+ T cells in 
response to TCR stimulation (159). Similar experiments also demonstrated great 
increases in overall thymocyte and peripheral T cell numbers as a result of NF1-
deficiency, also accompanied by a reduced ability to proliferate in response to stimuli 
even with concurrent increases in Ras-MAPK signaling, suggesting that NF1 acts to 
regulate steady-state proliferation in the T cell compartment (86). Further, several 
cases have been reported in which human NF1 patients were consequently diagnosed 
with the T cell-mediated autoimmune disorder multiple sclerosis, at rates higher than 
were expected given the statistics for the individual disorders (160-163). 
 
In these studies, we investigate the role of NF1 specifically in the T cell compartment 
through use of a Cre-LoxP conditional knockout mouse model (1). We report that 
NF1 is non-redundant and haploinsufficient in T cells with regards to thymocyte 
development and peripheral T cell homeostasis. We further report that homozygous 
inactivation of nf1 in T cells enhances infection clearance in a murine model of 
Listeria monocytogenes infection. The enhanced response to L. monocytogenes is 
likely due to increased expression of interferon-(IFN-) and the transcription factor 
Eomesodermin in naïve NF1-deficient CD8
+
 T cells, the population in which 
pathogen-specific cells would exist prior to infection. However, the mechanisms 
behind the increased effector function in naïve CD8
+
 T cells remain unclear. 
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2.3. Materials and Methods 
 
Mice 
nf1
fl/fl
 mice on a C57BL/6 x 129 Sv background were crossbred with plckcre Tg mice 
(Taconic) (164) to generate T cell-specific NF1-deficient (T cell KO) mice and Cre-
negative littermate controls. nf1
fl/fl
-plckcre mice were bred to wild-type C57BL/6 
mice (Jackson Labs) to generate mice that were heterozygous for the floxed nf1 allele 
in the T cell compartment, with (T cell Het) and without Cre. PCR genotyping for the 
floxed nf1 allele was done using a set of primers that distinguish between the wild-
type, floxed, and recombined floxed alleles, as previously described (1). T cell-
specific NF1-deficient TCR-transgenic mice were generated by crossbreeding nf1
fl/fl
-
plckcre mice to HY TCR Tg mice (Taconic). All animals were maintained in specific 
pathogen-free conditions at the University of Michigan Medical School unless 
otherwise specified. All experiments were performed in compliance with University 
of Michigan guidelines and were approved by the University Committee on the Use 
and Care of Animals. 
 
Peripheral T cell survival assay 
Pan-T cells were isolated from pooled spleen and lymph node suspensions using a 
MACS pan-T cell negative selection kit (Miltenyi). Purity of cells was routinely 
established at > 90% T cells via flow cytometry. Cells were plated at a concentration 
of 10
6
 cells/ml in RPMI 1640 containing 10% FBS and antibiotics (RPMI-FBS) at a 
final volume of 1 ml/well of a 24-well plate, with the addition or not of 5 ng/ml 
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recombinant murine IL-7 (R&D Systems). Cell viability was analyzed using flow 
cytometry after 72 hours in culture. 
 
Activation-induced cell death assay 
Pan-T cells were isolated as described above. T cells were stimulated at a 
concentration of 10
6
 cells/ml in a total volume of 1 ml per well in a 24-well plate that 
had been pre-coated with CD3 mAb (1 g/ml; eBioScience). CD28 mAb (1 g/ml; 
eBioScience) and recombinant murine IL-2 (100 ng/ml; R&D Systems) were added 
to all wells. T cells were harvested after 72 hours, washed twice, and replated in 
RPMI-FBS or RPMI with or without IL-2. Cell viability was analyzed by flow 
cytometry after 48 additional hours in culture. 
 
Stimulation of peripheral T cells 
Pan-T cells or CD8
+
 T cell populations were isolated as described above. T cells were 
stimulated at a concentration of 10
6
 cells/ml RPMI-FBS in a volume of 200 l/well of 
a 96-well U-bottomed plate. For CD3/CD28 mAb stimulation, wells were pre-coated 
with CD3 mAb, and soluble CD28 mAb was included in the culture medium. 
Neutralizing anti-IL-2 mAb (BD Pharmingen) was added to wells at 1 g/ml. 
Recombinant murine IL-2 was added to wells at 100 ng/ml. Cells were stimulated for 
48 hours unless otherwise indicated. 
 
HY TCR-tg T cells were stimulated at a concentration of 10
6
 cells/ml RPMI-FBS at a 
volume of 200 l/well of a 96-well U-bottomed plate. Irradiated adherent splenocytes 
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were used as antigen-presenting cells at a concentration of 10
6
 per well. Cells were 
stimulated with 1 or 10 g/ml HY peptide (New England Peptide) or not, or with 
CD3 and CD28 mAb as described previously. 
 
Helper T cell differentiation 
CD4
+
 T cells were isolated from pooled spleen and lymph node suspensions using a 
MACS CD4+ T cell negative selection kit (Miltenyi). CD4
+
 T cells were initially 
cultured at a density of 10
6
 cells per ml RPMI-FBS in 96-well plates that had been 
pre-coated with CD3 mAb. Control cells were plated in RPMI + 10% FBS alone. All 
initial skewing conditions received CD28 mAb at a final concentration of 1 g/ml. 
For Th0 skewing, 100 ng/ml IL-2 was added to the culture medium. For Th1 
skewing, IL-2 plus 10 ng/ml IL-12 (R&D Systems) and 10 g/ml IL-4 neutralizing 
mAb (BD Pharmingen) were added to the culture medium. For Th2 skewing, IL-2 
plus 10 ng/ml IL-4 (R&D Systems) and 10 g/ml IFN- neutralizing mAb (BD 
Biosciences) were added to the culture medium. For Th17 skewing, IL-2 and 
neutralizing mAb against IFN- and IL-4 as well as TGF- at 5 ng/ml, IL-6 at 10 
ng/ml, and IL-23 at 10 ng/ml (R&D Systems) were added to the culture medium.  
 
At 72 hours, cells in each well were transferred to a fresh well in a 48-well plate. Th0, 
Th1, and Th2 cells had 100 ng/ml IL-2 added to the culture medium for a final 
volume of 600 l. Th17 cells had 50 ng/ml IL-2, 5 ng/ml each IL-6 and IL-23, and 5 
ng/ml each of neutralizing IFN- and IL-4 mAb added to the culture medium for a 
final volume of 500 l. Cells were incubated in these conditions for 48 hours. 
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Cells were restimulated at a concentration of 10
6
 cells/ml in 96-well plates that had 
been pre-coated with anti-CD3. All conditions were plated in triplicate. Supernatants 
were removed from cultures 24 hours later and were analyzed by ELISA. 
 
Generation of CD4+ and CD8+ T cell blasts 
Freshly isolated CD8
+ 
or naïve CD4
+
 T cells from NF1 KO and control littermate 
mice were cultured in RPMI-FBS in 24-well plates that had been previously coated 
with CD3 mAb. 1 g/ml CD28 mAb and 100 ng/ml IL-2 were added to the culture 
medium. Cells were initially plated at a volume of 1 ml per well and a density of 
2x10
6
 cells/ml. After 72 hours (CD8
+
 T cells) or 96 hours (naïve CD4
+ 
T cells), cells 
from each well were transferred to wells of a fresh 6-well plate. RPMI-FBS plus 100 
ng/ml IL-2 was added to each well to a final volume of 5 ml per well. After 48 hours, 
cells were harvested, washed 1X in fresh RPMI, and plated in fresh 6-well plates or 
T-75 flasks at a density of 1-1.5x10
6
/ml in RPMI+10% FCS. Cells were harvested the 
following day for use in functional assays. 
 
Flow cytometry 
Single-cell suspensions of freshly isolated thymocytes, spleens and lymph nodes were 
analyzed for cell surface expression of CD4, CD8 and CD44 by flow cytometry using 
fluorochrome-labeled mAb (BD Pharmingen). Thymocytes were further analyzed for 
surface expression of CD25 and T3.70 (HY TCR) using fluorochrome-labeled mAb 
(BD Pharmingen and eBioscience). For proliferation experiments, cells were labeled 
with CFSE prior to stimulation or not as indicated above. For survival and cell death 
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experiments, unfixed cells were labeled or not with fluorochrome-labeled Annexin-V 
and 7-AAD for 10 minutes prior to analysis. For intracellular staining, cells were 
treated with PMA and ionomycin (50 ng/ml and 1.5 M respectively; Sigma Aldrich) 
for 5 h with addition of brefeldin A (1:1000 dilution of stock; BD Biosciences) for the 
last 4 h of culture. Cells were surface stained with mAb against CD4, CD8 and CD44 
prior to fixation and permeabilization and staining for intracellular expression of IFN-
, Eomes and T-bet (eBioscience except IFN-, which was purchased from BD 
Pharmingen). Cellular data were collected on a FACSCanto flow cytometer equipped 
with FACSDiva software (BD Biosciences). 
 
ELISA  
Concentrations of IFN-in pan-T or CD8+ T cell culture supernatants were 
determined using a Duo-set ELISA kit (R&D Systems) according to manufacturer 
specifications. Concentrations of IFN-, IL-4 and IL-17 in CD4+ Th culture 
supernatants were determined with the use of Duo-set ELISA kits (R&D Systems).  
 
In-vitro signaling and immunoblotting 
For TCR signaling experiments, 5x10
5
 to 10
6
 CD4
+
 or CD8
+
 T cells were treated as 
follows: CD3/CD28-stimulated cells were resuspended in RPMI containing 5 g/ml 
anti-mouse CD3 and CD28 mAbs (eBioscience) and incubated for 20 minutes on ice. 
Cells reserved for the “zero” timepoint were incubated in RPMI without antibodies 
for 20 minutes on ice. 10 l of RPMI containing 50 g/ml goat anti-Armenian 
hamster IgG (Jackson Immunolabs) was then added to all tubes to crosslink the bound 
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primary antibodies. All cells were incubated in a 37 C water bath for the indicated 
timepoints. Cells reserved for the “zero” timepoint were incubated at 37 C for 2 or 5 
minutes. Cells were chilled on ice, pelleted briefly, and supernatants were removed 
and replaced with 1x SDS-PAGE sample buffer containing protease inhibitor cocktail 
(Roche) and sodium orthovanadate. All samples were boiled for at least 10 minutes 
prior to separation on 10% acrylamide/bis tris-glycine SDS-PAGE gels followed by 
transfer to PVDF membranes. Blots were probed with antibodies against phospho-
ERK1/2, total ERK1/2, phospho-Akt, total Akt, phospho-p70S6K, and total p70S6K 
(Cell Signaling). 
 
Listeria monocytogenes infection 
nf1
fl/fl
-plckcre and Cre-negative littermate controls were injected intraperitoneally 
with 5x10
5
 L. monocytogenes CFU as previously described (165). Five days post-
infection, spleens and livers were harvested and homogenized. Organ homogenates 
were plated via serial dilution on LB-agar and were incubated for 24 hours prior to 
counting formed colonies. 
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2.4. Results 
 
Generation of T cell-specific NF1-deficient mice 
In order to investigate the effects of NF1 loss in T cells, we needed to circumvent the 
issue of embryonic lethality that was reported to occur in mice that were homozygous 
for a null allele of nf1 (30, 31). We accomplished this through the use of Cre-LoxP 
conditional knockout technology. Mice bearing a flanked-by-LoxP (floxed) allele of 
nf1, the gene that codes for the protein NF1, were previously generated (1). In the 
targeted allele, exons 31 and 32 of nf1 are floxed (Fig. 2.1). Exon 31 had been chosen 
for deletion in the design of both nf1 null alleles that previously led to embryonic 
lethality as it is a site of  observed mutations in three human families affected by the 
disorder NF1 (30, 31, 166), and for this reason it was chosen for recombination in the 
floxed allele. The non-recombined floxed allele of nf1 has been demonstrated to act 
indistinguishably from wild-type alleles, and the recombined floxed allele acts as a 
null allele, indicating that this is an excellent model with which to circumvent 
embryonic lethality and study gene and protein deletion in adult mice (1). 
 
To recombine nf1 specifically in the T cell compartment, nf1
fl/fl
 mice were crossed 
with mice bearing the Cre transgene under the control of the proximal Lck promoter 
(plckcre) to generate nf1
fl/fl
-plckcre (T cell KO) mice and Cre-negative littermate 
controls. The proximal Lck promoter induces expression exclusively in the T cell 
compartment at the DN3 stage of thymocyte development, allowing for gene 
inactivation prior to thymic selection and maturation events (164). Due to technical 
issues, rather than assessing protein deletion by western blotting, we chose to analyze 
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gene recombination using PCR as the recombined allele had been previously 
established to act as a null allele (1). As seen in Figure 4, expression of the plckcre 
transgene consistently results in complete recombination of the floxed nf1 locus in 
both thymocytes and peripheral T cells. Low expression of the non-recombined 
floxed allele that is observed in peripheral T cell PCR samples is likely from residual 
B cells or myeloid cells that are present due to imperfect magnetic cell sorting, as 
thymocyte samples from the same mice show complete recombination of the floxed 
nf1 allele (Fig. 4). We are confident that the experiments described herein are an 
analysis of full deletion of NF1 in the T cell compartment. 
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Figure 4. Genotyping of T cell-specific NF1-deficient mice. 
Conditional deletion of NF1 was achieved using previously generated mice 
that bear flanked-by-loxP (floxed) alleles of nf1. Top, diagram showing the 
position of genotyping primers (P1, P2, P3) on the nf1 locus. LoxP sites  
(filled triangles) surround exons 31 and 32, which were previously described 
to be essential to NF1 function (1). Bottom, T cell-specific deletion of NF1 
was achieved via breeding of nf1
fl/fl
 mice with plckcre transgenic mice. 
Recombination of the floxed nf1 allele in thymocyte (T) and peripheral T cell 
(P) compartments for one control and two T cell KO mice were confirmed by 
PCR. Data are representative of multiple experiments. 
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Thymic cellularity in T cell-specific NF1-deficient mice 
Upon generation of nf1
fl/fl
-plckcre (T cell KO) mice and appropriate Cre-negative 
littermate controls, we first investigated cellularity within the thymus to determine the 
effects, if any, of NF1 loss on thymocyte development. ERK activation is well 
established as a dominant factor in thymic selection (63), so we thought it possible 
that perturbation of Ras-ERK signaling via deletion of NF1 could affect selection 
dynamics as well as thymocyte numbers and subset frequencies. Flow cytometric 
analysis of thymocytes from T cell KO and control mice demonstrated that gross 
thymocyte development is moderately affected by NF1 deficiency (Fig. 5A). T cell 
KO mice had significantly fewer CD4 and CD8 single positive (SP) thymocytes, both 
in frequency of total thymocytes as well as in absolute numbers. A slight but 
significant difference in DP numbers did not translate into a significant difference in 
the frequency of DP cells. Conversely, although DN cell numbers were not 
significantly different, T cell KO mice had a slight but significant increase in DN cell 
frequency. Analysis of the developmental subsets within DN cells revealed that the 
frequency of DN3 cells was significantly increased in NF1 KO mice, along with a 
corresponding decrease in the frequency of DN4 cells (Fig. 5B), indicating a potential 
block in the transition from DN3 to DN4. Analysis of absolute cell numbers within 
the DN population showed a significant increase in T cell KO mice in the DN3 subset 
(Fig. 5B). 
 
We also investigated thymic cellularity in nf1
fl/+
-plckcre (T cell Het) and littermate 
control mice. Mutation of a single allele of nf1 has been shown to be causative in the 
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disorder NF1, and the potential effects of heterozygosity on thymocyte development 
had not been explored in detail (50, 51, 86). We found that T cell Het thymocytes 
showed slight but significant increases in both the frequency and total cell number in 
the DN thymic subset (Fig. 6A). Contrary to our observations in T cell KO mice (Fig. 
6A), we observed no other significant changes in other thymocyte populations in T 
cell Het mice. Further analysis of the DN population indicated that the frequencies of 
DN2 and DN3 cells were significantly increased in NF1 het mice, along with a 
significant decrease in the frequency of T cell Het DN 4 cells (Fig. 6B). Analysis of 
DN cell numbers show that the absolute numbers of all DN cell populations are 
significantly increased in T cell Het mice (Fig. 6B). We note that the increases in 
DN3 cells are similar in mice with homozygous and heterozygous deletions of NF1, 
suggesting that NF1 is haploinsufficient with regards to thymocyte development. 
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Figure 5. Thymic cellularity in T cell-specific NF1-deficient mice.  
A, Thymocytes from T cell KO and control mice were analyzed by flow 
cytometry. Left, representative CD4 vs CD8 flow cytometry plots to 
demonstrate population analysis. Numbers in dot plot corners represent 
population frequency. Right, graphical analysis of thymic subset populations. 
B, Developmental subsets of DN thymocytes from T cell KO and control mice 
were analyzed by flow cytometry. Left, representative CD44 vs. CD25 flow 
cytometry plots. Right, graphical representation of DN subset frequencies. All 
graphs show the mean + SEM. n = 26 for control and T cell KO mice (A), n = 
22 for control and T cell KO mice (B). Statistical significance was determined 
using the unpaired one-tailed Student‟s t-test. *p < 0.05, **p < 0.01. 
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Figure 6. Thymic cellularity in T cell-specific NF1-heterozygous mice.  
A, Thymocytes from T cell Het and control mice were analyzed by flow 
cytometry. Left, representative CD4 vs. CD8 flow cytometry dot plots to 
demonstrate population analysis. Numbers in dot plot corners represent 
population frequency. Right, graphical analysis of thymic subset populations. 
B, Developmental subsets of DN thymocytes from T cell Het and control mice 
were analyzed by flow cytometry. Left, representative CD44 vs. CD25 flow 
cytometry plots. Right, graphical representation of DN subset frequencies. All 
graphs show the mean + SEM. n = 9 for control mice and 14 for T cell Het 
mice (A), and n = 7 for control mice and 10 for T cell Het mice (B). Statistical 
significance was determined using the unpaired one-tailed Student‟s t-test. *p 
< 0.05, **p < 0.01, ***p < 0.001. 
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Peripheral cellularity in T cell-specific NF1-deficient mice 
Loss of NF1 in thymocyte precursor cells has been shown previously to result in 
increased numbers of peripheral T cells in murine adoptive transfer models (86). 
Unexpectedly, we observed modest but significant decreases in CD4 and CD8 SP 
cells in T cell KO mice (Fig. 5A). To determine if peripheral T cell populations were 
similarly affected by the loss of NF1, we investigated the cellularity of splenocytes 
and lymph node cells from T cell KO and littermate control mice. Flow cytometric 
analysis showed striking and statistically significant decreases in CD4
+
 and CD8
+
 T 
cell numbers and frequencies in both spleen and lymph node cell populations (Fig. 
7A). We initially observed higher frequencies of CD44
hi
 T cells in the peripheral 
CD4
+
 and CD8
+
 compartments in T cell KO mice (Fig. 7B). However, analysis of cell 
numbers within the CD4
+
 and CD8
+
 T cell subsets indicated to us that in fact, the 
numbers of CD44
hi
 T cells were unchanged in NF1 KO mice. On the contrary, the 
increased frequencies of CD44
hi
 cells in these mice were due to large, statistically 
significant decreases in CD44
lo 
naïve T cells in both the CD4
+ 
and CD8
+
 
compartments (Fig. 7B). Analysis of T cell Het mice demonstrated a similar 
significant reduction in peripheral T cell numbers (Fig. 8A). We further observed that 
the reductions in T cell numbers in NF1 Het mice were due to significant decreases in 
CD44
lo
 naïve T cells specifically, similar to what we had observed in T cell KO mice 
(Fig. 8B).  
 
Diminished numbers of peripheral T cells in T cell KO mice, especially in the naïve 
cell compartments, could be attributed to a reduced ability of these cells to respond to 
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pro-survival signals in the periphery, and thus to reduced survival. IL-7 is well-known 
to be an essential cytokine for the promotion of naïve and memory T cell survival in 
the periphery (167). To determine if NF1-deficiency resulted in a reduced ability of 
cells to respond positively to IL-7, we cultured pan-T cells from T cell KO and 
control mice with IL-7 or not. After 72 hours, we assessed cell viability using flow 
cytometry. We observed no differences in pan-T cell survival between T cell KO and 
control cells (Fig. 9, left). Further analysis of CD4
+ 
and CD8
+
 naïve and memory-like 
T cell subsets demonstrated that, again, there were no differences in IL-7-mediated 
survival between T cell KO and control T cells (Fig. 9, right). 
 
We also wished to determine whether NF1-deficient T cells were more susceptible to 
activation-induced cell death (AICD). Following an adaptive immune response, the 
majority of active Ag-specific T cells undergo apoptosis upon the withdrawal of IL-2 
(79). We considered the possibility that T cell KO T cells might respond abnormally 
to homeostatic conditions and thus might be more susceptible to AICD in resting 
conditions. Increased AICD might account for the reduced numbers of peripheral 
naïve T cells in T cell KO mice. To determine this, we cultured pan-T cells with 
CD3/CD28 mAb in the presence of IL-2 for 72 hours. We then replated the cells in 
medium with or without FBS, IL-2, or both, and analyzed cell viability after a further 
48 hours of culture. We observed little difference in cell viability between T cell KO 
and control T cells in any of the conditions studied (Fig. 10). Thus, we conclude that 
NF1 is likely not a major factor in the contraction of the T cell-mediated adaptive 
immune response. 
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Peripheral T cells undergo proliferation to increase the number of T cells and 
maintain homeostasis (74). Ras signaling, Erk2 activation in particular, has been 
reported as an important regulator of CD8
+
 T cell proliferation (64). However, the 
reduced numbers of peripheral naïve T cells in T cell KO mice indicated that perhaps 
homeostatic proliferation was defective. We assessed the proliferative capabilities of 
NF1 KO T cells in vitro. Analysis of CFSE-labeled pan-T cells from NF1 KO and 
control mice that had been stimulated with CD3/CD28 mAb for 72 hours revealed no 
apparent differences in CD4
+
 or CD8
+
 T cell proliferative responses between NF1 KO 
and control T cells (Fig. 11).  
 
We expected that the effects of NF1, as a negative regulator of Ras, might be best 
observed in the cellular signaling pathways that are downstream of Ras activation. 
Ras activation is well-known to upregulate activation of the protein ERK, a member 
of the MAPK family (8). As Ras had been previously shown to be hyperactivated in T 
cells that had developed from NF1-deficient bone marrow (86), we expected that this 
may be true in T cells from our T cell-specific NF1-deficient mice. To investigate 
potential Ras-ERK signaling irregularities, we isolated CD4
+
 or CD8
+
 T cells from 
the spleens and lymph nodes of naïve mice and stimulated them in vitro for a short 
time course with anti-CD3 and anti-CD28, followed by lysis and Western blotting. 
However, we observed no increase in Ras-ERK activation in NF1-deficient T cells as 
measured by ERK phosphorylation (Fig. 12).  We next analyzed activation of Akt in 
CD8
+
 T cells, as Ras signaling can promote Akt phosphorylation by activation of 
PI3K (9). We also analyzed phosphorylation of the mTOR1 pathway component 
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p70S6 kinase, as mTOR is known to be activated downstream of Akt (10). Analysis 
of Akt phosphorylation in these cells as well as that of the mTOR pathway 
component p70S6K similarly failed to show evidence of increased Ras signaling in 
the absence of NF1 expression (Fig. 12). Thus, the mechanisms that underlie the 
reduction in peripheral naïve T cell numbers in T cell KO mice remain unclear. 
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Figure 7. Peripheral cellularity in T cell-specific NF1-deficient mice.  
A, peripheral T cell populations from T cell KO and control mice were 
analyzed by flow cytometry. Left, representative CD4 vs. CD8 dotplot to 
demonstrate gating. Numbers in dot plot corners represent population 
frequency. Right, graphical representation of CD4+ and CD8+ T cell 
populations in the spleen and lymph nodes. B, CD4+ and CD8+ T cells from T 
cell KO and control mice were analyzed by flow cytometry for the presence of 
the memory marker CD44. Left, representative histograms demonstrating the 
frequency of CD44
hi 
cells in splenic T cells. Right, enumeration of CD44
lo
 and 
CD44
hi
 subsets within peripheral T cell populations. All graphs show the mean 
+ SEM. n = at least 21 for control and 22 for NF1 KO mice. Statistical 
significance was determined using the unpaired one-tailed Student‟s t-test. 
***p < 0.001. 
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Figure 8. Peripheral cellularity in T cell-specific NF1-heterozygous mice.  
A, peripheral T cell populations from NF1 Het and control mice were analyzed 
by flow cytometry. Left, representative CD4 vs. CD8 dotplot to demonstrate 
gating. Numbers in dot plot corners represent population frequency. Right, 
graphical representation of CD4+ and CD8+ T cell populations in the spleen 
and lymph nodes. B, CD4+ and CD8+ T cells from NF1 Het and control mice 
were analyzed by flow cytometry for the presence of the memory marker 
CD44. Left, representative histograms demonstrating the frequency of CD44hi 
cells in splenic T cells. Right, enumeration of CD44 lo and CD44hi subsets 
within peripheral T cell populations. All graphs show the mean + SEM. n = at 
least 6 for control and 10 for NF1 het mice. Statistical significance was 
determined using the unpaired one-tailed Student‟s t-test. *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 9. NF1-deficient peripheral T cells do not respond abnormally to 
IL-7. 
 Left, representative dot plots of total pan-T cells from T cell KO and control 
mice. Cells were treated with or without IL-7 for 72 hours prior to analysis of 
cell viability. Right, IL-7 survival index was determined as the ratio of 
Annexin-V/7-AAD double-negative T cells in IL-7-treated cells vs. untreated 
cells. Ratios were determined separately for each of the indicated peripheral T 
cell subsets. The graph shows the mean + SEM. n = 3 mice for each genotype. 
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Figure 10. NF1-deficiency does not affect activation-induced T cell death 
(AICD) in CD8+ T cells.  
Freshly isolated T cell KO and control pan-T cells were stimulated with CD3 
and CD28 mAb and IL-2 for 72 hours prior to 48 hours of culture in the 
indicated conditions. Cell viability was assessed using Annexin-V and 7-
7AAD staining as described in Figure 9. Cell viability is represented as a 
percentage of viable FCS+IL-2-treated cells. All graphs show the mean + 
SEM. n = at least 3 mice per genotype. Statistical significance was determined 
using the unpaired one-tailed Student‟s t-test.  * p < 0.05. 
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Figure 11. NF1-deficiency does not affect activation-induced T cell 
proliferation.  
Freshly isolated T cell KO and control pan-T cells were labeled with CFSE 
prior to stimulation with CD3 and CD28 mAb. Cell division was analyzed by 
flow cytometry following 72 hours of culture. Left, representative CFSE vs. 
forward scatter dot plots of CD4+ and CD8+ T cells from T cell KO and 
control mice. Right, cell divisions represented as a percentage of total CD4+ 
and CD8+ T cells. All graphs show the mean + SEM. n = 4 mice per genotype. 
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Figure 12. NF1-deficiency does not yield increased Ras signaling in freshly 
isolated T cells.  
Freshly isolated T cell KO and control CD4+ or CD8+ T cells were stimulated 
with anti-CD3 and anti-CD28 in vitro for the indicated times. Cells were lysed 
and proteins were separated using SDS-PAGE. Phosphorylation of ERK, Akt, 
and p70S6K were detected via Western blotting of proteins that had been 
transferred to PVDF membrane. Data are representative of multiple 
experiments. 
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Analysis of CD8+ T cell effector function in NF1-deficient T cells 
T cells are critical to the development of adaptive immunity against pathogens, to the 
extent that humans and mice with severe T cell deficiencies have a very high 
mortality rate early in life (87, 88). Thus, as our NF1-deficient mice possessed 
significantly reduced numbers of peripheral naïve T cells, we hypothesized that these 
mice might have a reduced ability to mount a T cell-mediated response against a 
pathogen, as pathogen-specific T cells would reside within the naïve compartment. 
We chose Listeria monocytogenes as it is an intracellular pathogen and the host must 
be able to induce activation of CD8
+
 T cells to clear the infection fully and efficiently 
(168). We injected T cell KO and control mice intraperitoneally with L. 
monocytogenes and monitored the mice for five days to allow for initiation of an 
adaptive immune response. We then harvested the spleens and cultured spleen 
homogenates to determine the number of remaining L. monocytogenes colony-
forming units (CFU). Unexpectedly, we determined that NF1 KO mice were better 
able to clear L. monocytogenes as determined by CFU counts (Fig. 13). 
 
Although CD8
+
 T cells are the primary effector cells in the host response to L. 
monocytogenes, CD8
+
 T cells do require help from CD4
+
 T cells, primarily in the 
form of IL-2, during the course of initial activation in the lymph nodes (112). We 
considered the possibility that increased cytokine production from NF1-deficient 
CD4
+
 T cells could promote CD8
+
 T cell activation and effector function and that we 
may be able to more easily observe such changes in vitro. We cultured freshly 
isolated pan-T cells from T cell KO and control mice with or without anti-CD3 and 
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anti-CD28 (CD3/CD28) for 48 hours. We analyzed the cells for the expression of IL-
2 as well as the effector cytokine IFN- by intracellular cytokine staining and flow 
cytometry. We found that T cell KO CD4
+
 T cells did not differ significantly from 
control cells in cytokine expression when stimulated with CD3/CD28 (Fig. 14). In 
CD3/CD28-stimulated T cell KO CD8
+
 T cells, we noted a significant increase in the 
expression of both IL-2 and IFN- in the naïve cell compartment only (Fig. 14). 
Analysis of cytokine expression in T cell Het and control pan-T cell cultures 
demonstrated no increase in T cell Het CD8
+
 IFN- expression (Fig. 15). 
 
We next examined the expression of IFN- in stimulated CD8+ T cell cultures. We 
stimulated CD8
+
 T cells with CD3/CD28 alone or in the presence of IL-2, to mimic 
CD4+ T cell help,  or IL-4, a CD4
+
 T cell produced cytokine that shares a receptor 
subunit with IL-2. We then determined the frequency of IFN--positive cells using 
intracellular cytokine staining and flow cytometry. We observed no significant 
changes between T cell KO and control cells in the frequencies of IFN--positive 
cells in CD44
hi
 CD8
+
 T cells (Fig. 16A). However, we did find significantly increased 
frequencies of IFN--positive cells in T cell KO CD44lo CD8+ T cells that were 
stimulated with CD3/CD28 alone (Fig. 16A). We also analyzed levels of secreted 
IFN-in supernatants from the stimulated T cell KO and control CD8+ T cell cultures 
that were described in Figure 16A. Using ELISA, we determined that T cell KO cells 
did secrete significantly higher levels of IFN- in response to all stimuli (Fig. 16B). 
Calculation of the ratio of T cell KO over control IFN- secretion demonstrated the 
greatest fold difference in cytokine secretion in the cells treated with only 
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CD3/CD28; addition of cytokine stimulation reduces the difference in cytokine 
secretion between T cell KO and control cells (Fig. 16B). A caveat is that the 
increased frequency of CD44
hi
 T cells in T cell KO mice makes it impossible to 
determine whether the increased IFN- secretion is due to CD44hi cells or to 
increased activity by T cell KO naïve CD8
+
 T cells (Fig. 16A). 
 
The transcription factors Eomesodermin (Eomes) and T-bet are critical determinants 
in CD8
+
 T cell effector and memory fate decisions (114, 116). We were curious 
whether increased expression of Eomes and T-bet could account for the increased 
expression of IFN- in naïve T cell KO CD8+ cells (Fig. 16A). We used intracellular 
staining and flow cytometry to determine the frequency of expression of Eomes and 
T-bet in CD8
+
 T cells that had been stimulated with CD3/CD28 in the presence or 
absence of IL-2 or IL-4. Similar to our observations with IFN- expression, we 
observed significant increases in Eomes expression following stimulation only in T 
cell KO naïve CD8
+
 T cells, although we did note increased basal levels of Eomes 
expression in CD44
hi 
T cell KO CD8
+ 
cells (Fig. 17). T-bet expression was 
significantly increased only in T cell KO CD44
lo
 cells following stimulation (Fig. 18).  
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Figure 13. Response to Listeria monocytogenes in NF1-deficient mice.  
NF1 KO and control mice were injected intraperitoneally with 5x10
4
 colony-
forming units (CFU) of L. monocytogenes. Mice were sacrificed five days 
later, spleens were harvested, and spleen homogenates were incubated on LB-
agar. CFU were counted 24 hours later. N = 5 for control and NF1 KO mice. 
Statistical significance was determined using the unpaired one-tailed Student‟s 
t-test. *p < 0.05. 
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Figure 14. Analysis of NF1-deficient T cell cytokine production.  
Freshly isolated T cell KO and control pan-T cells were cultured with CD3 
and CD28 mAb or not for 48 hours prior to restimulation with PMA and 
calcium ionophores. IL-2 and IFN- cytokine production were determined 
using flow cytometry. Top, representative flow plots of T cell KO and control 
CD4+ and CD8+ T cells from pan-T cell cultures. Bottom, CD4+ and CD8+ T 
cell subsets represented as percent cytokine-positive cells of total CD44
lo
 and 
CD44
hi
 cells. All graphs show mean + SEM. n = at least three mice per 
genotype. Statistical significance was determined using the unpaired two-
tailed Student‟s t-test. *p < 0.05, **p < 0.01. 
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Figure 15. NF1-heterozygosity does not affect T cell effector function.   
Pan-T cells from T cell KO and control mice were stimulated or not with CD3 
and CD28 mAb for 48 hours. IFN- expression in CD4+ (A) and CD8+ T cells 
(B) was determined by flow cytometry. Graphs show the mean + SEM. n = 4 
for each genotype.  
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Figure 16. NF1-deficiency promotes naive CD8+ T cell effector function on a 
per-cell basis.  
A, freshly isolated peripheral CD8+ T cells from T cell KO and control mice were 
stimulated for 48 hours with CD3 and CD28 mAb or not, in the presence or absence 
of rIL-2 or rIL-4, followed by restimulation with PMA and ionomycin. Cellular IFN- 
expression was determined by flow cytometry. Top, representative dotplots of CD44 
vs. IFN- expression. Bottom, IFN--positive cells expressed as a percentage of total 
CD44lo or CD44hi cells. B, CD8+ T cells were stimulated as in (A). Supernatants 
from these cultures were analyzed for IFN- secretion using ELISA. Left, comparison 
of IFN- secretion. Right, ratios of KO IFN- secretion to WT IFN- secretion. All 
graphs show mean + SEM. n = at least three mice per genotype. Statistical 
significance was determined using the unpaired one-tailed Student‟s t-test. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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Figure 17. Expression of Eomesodermin in NF1-deficient CD8+ T cells.  
Freshly isolated peripheral CD8+ T cells from T cell KO and control mice 
were stimulated for 48 hours with CD3 and CD28 mAb or not, in the presence 
or absence of rIL-2. Cells were restimulated with PMA and ionomycin prior to 
analysis of intracellular Eomes expression using flow cytometry. Top, 
representative dotplots of CD44 vs. Eomes expression. Bottom, Eomes-
positive cells as a percent of total CD44lo or CD44hi cells. Graphs show the 
mean + SEM. n = 5 mice per genotype. Statistical significance was determined 
using the unpaired one-tailed Student‟s t-test. *p < 0.05. 
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Figure 18. Expression of T-bet in NF1-deficient CD8+ T cells.  
Freshly isolated peripheral CD8+ T cells from T cell KO and control mice 
were stimulated for 48 hours with CD3 and CD28 mAb or not, in the presence 
or absence of rIL-2. Cells were restimulated with PMA and ionomycin prior to 
analysis of intracellular T-bet expression using flow cytometry. Top, 
representative dotplots of CD44 vs. T-bet expression. Bottom, T-bet-positive 
cells as a percent of total CD44lo or CD44hi cells. Graphs show the mean+ 
SEM. n = 4 mice per genotype. Statistical significance was determined using 
the unpaired one-tailed Student‟s t-test. *p < 0.05. 
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Helper-T cell differentiation in NF1-deficient CD4
+
 T cells 
Although CD8
+
 T cells are the primary effector cells in the immune response against 
L. monocytogenes, CD4
+ 
T cells not only direct the course of the adaptive response to 
infections but also provide cytokine help that promotes the activation of CD8
+
 T cells, 
primarily in the form of IL-2 (112). Thus we considered it important to determine if 
the loss of NF1 had any significant impact on the effector function of CD4
+
 T cells. 
We cultured isolated CD4
+
 T cells under helper-T cell skewing conditions for 120 
hours prior to restimulation with CD3 mAb. 24 hours later, supernatants from these 
skewing cultures were analyzed by ELISA for the secretion of IFN, IL-4 and IL-7, 
cytokines known to be produced following  Th1, Th2, and Th17 skewing, 
respectively. We noted that NF1 deficient T cells appeared to respond similarly to 
control T cells with regards the production of each cytokine under the conditions that 
would be expected to induce it (Fig,. 19A-C). Curiously, we also noted that NF1-
deficient T cells expressed higher amounts of cytokines that would not be expected to 
be induced under the initial skewing conditions. Most notably, NF1-deficient T cells 
secreted significantly higher amounts of IFN- under conditions that would be 
expected to suppress IFN- expression and instead promote IL-4 or IL-17 expression 
(Fig. 19A). We further observed similar albeit lesser increases in IL-4 and IL-17 
secretion under non-Th2 or non-Th17 conditions (Fig. 19B,C). 
 
One caveat of the T helper cell skewing experiments is that NF1-deficient T cell 
populations have a higher frequency of CD44
hi
 memory-like cells. Although the 
actual numbers of CD44
hi
 cells are unchanged within the peripheral lymphoid organs, 
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the decreased numbers of CD44
lo
 cells means that the resulting increase in CD44
hi 
to 
CD44
lo
 ratio must be taken into account. We noted that the increased frequency of 
CD44
hi
 cells could be responsible for the increase in cytokine production observed in 
Figure 19A-C. The presence of an activated phenotype on these cells could also 
indicate that the cells had been previously committed to a Th lineage in vivo, which 
would account for the increased Th subset plasticity that we observed. 
 
We did not previously observe differences in the strength or kinetics of Ras-ERK 
signaling in freshly isolated CD4
+
 T cells (Fig. 12), but we wished to determine if 
perhaps differences in ERK phosphorylation, which may explain the abnormal 
cytokine secretion in Fig. 19A-C, would be evident in blasts generated from naïve 
CD4+ T cells. Western blotting of CD4
+ 
T cell blast lysates demonstrated no 
consistent increase in Ras-ERK signaling upon restimulation between T cell KO and 
control cells (Fig. 19D). We conclude that the Th plasticity that we observed in NF1-
deficient CD4
+
 T cells is the result of in vivo activation and subset differentiation. 
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Figure 19. Plasticity in differentiated helper-T cells.  
Freshly isolated CD4+ T cells from T cell KO and control mice were 
stimulated for 5 days under the indicated helper-T cell skewing conditions or 
not, followed by restimulation with CD3 mAb for 24 hours. Supernatants from 
restimulation cultures were analyzed by ELISA for IFN- (A), IL-4 (B) or IL-
17 (C). D, CD4+ T cell blasts were analyzed by western blotting following 
CD3+CD28 mAb stimulation. Graphs show the mean + SEM. n = 6 for both 
genotypes (A-C). Data are representative of multiple experiments (D). 
Statistical significance was determined using the unpaired one-tailed Student‟s 
t-test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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NF1-deficiency affects TCR-transgenic thymocyte development 
We observed earlier that NF1-deficiency moderately affects thymocyte subset 
populations but has a considerable effect on peripheral T cell populations, although 
we could not ascertain the reasons behind the observed peripheral naïve T cell losses 
seen in NF1-deficient mice (Fig. 5-9, 11,12).  However, it is possible that we are 
unable to adequately observe abnormal thymocyte events within a polyclonal T cell 
population. Abnormal thymic selection of a clonal population might not be 
observable within the polyclonal thymus, although it could have considerable impacts 
on peripheral T cell maintenance and function. The use of TCR-transgenic mice 
allows for the study of a clonal T cell population during development in the thymus 
as well as of peripheral homeostasis and effector function.  
 
We chose to investigate cellularity within NF1-deficient mice that are transgenic for 
the HY TCR (HY TCR-tg), which recognizes a peptide from the male HY antigen in 
the context of MHC class 1 receptor H-2D
b
 (169). This peptide is recognized as self-
antigen in male mice, leading to the deletion of all HY TCR-expressing T cells at the 
thymic negative selection checkpoint. In female mice, this transgenic TCR permits 
positive selection of HY TCR-positive thymocytes on thymic APCs that express H-
2Db. As such, in female mice, all mature HY TCR-positive T cells should express 
CD8
+
. This TCR-transgenic mouse model allows for the analysis of positive thymic 
selection in a clonal thymocyte population, as well as the analysis of peripheral 
survival of a clonal T cell population and antigen-specific CD8
+
 T cell effector 
function. 
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Thymic cellularity analysis of T cell KO and control HY TCR-tg female mice first 
revealed that a significantly lower percentage of thymocytes expressed the HY TCR 
in T cell KO mice as compared to littermate controls (Fig. 20A). We concluded that 
the reduced frequency of T cell KO HY TCR-positive thymocytes was due to 
decreased positive selection. To better address the possibility of defective positive 
selection in T cell KO mice, we looked at developmental subsets within the HY TCR-
positive cells. Similarly to polyclonal thymocytes, HY TCR cells transition from the 
DN to DP to CD8 SP stage, and in a clonal population, disturbances in this 
progression may be more readily apparent. In analysis of CD4 and CD8 expression on 
HY TCR-positive thymocytes, we observed that NF1-deficient thymocytes appeared 
to be partially blocked at the transition from DP to CD8 SP. Analysis of the CD8 SP 
to DP ratio revealed that, although it is approximately 3:1 in control thymocytes, the 
ratio is reduced to 1:1 in NF1-deficent animals (Fig. 20B). This indicates that perhaps 
NF1-deficiency results in a reduced ability to transition normally through thymic 
development and that the death of cells that fail positive selection could account for 
the reduced frequency of HY TCR-positive thymocytes. 
 
We were interested to determine if the previously observed peripheral T cell 
homeostatic abnormalities that we observed in polyclonal T cell KO mice were 
present in the clonal TCR-transgenic peripheral T cell population or in the non-
transgenic cells. Analysis of total T cell populations in the spleens of HY TCR-
transgenic mice demonstrated that T cell KO HY
+
 cells were present in similar 
frequencies and numbers as those observed in non-Cre mice (Fig. 21A). In the HY-
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negative compartment, we did observe a modest but significant reduction in 
peripheral CD4
+
 T cells in NF1-deficient mice, although this was not accompanied by 
the reduction in CD8
+
 T cell frequency and numbers that we had observed in 
polyclonal T cell populations (Fig. 7, 8, 21B ). Furthermore, in the HY-negative 
population, we failed to observe the losses in peripheral naïve T cells that we had 
observed in polyclonal T cell populations (Fig. 7, 8, 21B). 
 
We also wished to address the issue of effector T cell function in a clonal population 
that had been stimulated with cognate antigen-MHC complex. The use of a specific 
peptide antigen allows for more physiologically relevant stimulation of T cells, and it 
is possible that responses to specific antigens would not be observed in a broadly-
stimulated polyclonal setting. We stimulated peripheral CD8
+
 T cells from T cell KO 
and littermate control HY TCR-tg mice with HY peptide-pulsed antigen-presenting 
cells for 48 hours to induce expression of effector proteins, along with CD3 and 
CD28 mAb as a control to assess the level of stimulation. Using flow cytometry, we 
determined that the expression of IFN-, Eomes and T-bet in HY TCR-positive cells 
was not significantly different in NF1-deficient CD8
+
 T cell cultures in response to 
antigen stimulation (Fig. 22).  
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Figure 20. NF1-deficiency affects thymocyte development and cellularity 
in HY TCR-transgenic mice.  
A, representative histograms showing HY TCR expression on thymocytes 
(left) and HY TCR-positive percentage of total thymocytes (right). B, 
representative dotplots showing CD4 and CD8 expression on HY TCR-
positive thymocytes (left) and ratios of CD8 SP to DP cells (right). Graphs 
show the mean + SEM. n = 3 mice per genotype. Statistical significance was 
determined using the unpaired one-tailed Student‟s t-test. *p < 0.05. 
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Figure 21. NF1-deficiency affects peripheral CD4+ T cell homeostasis in 
HY TCR-transgenic mice.  
A, left, representative histograms showing HY TCR expression on T cell KO 
and control splenocytes. Right, percentage and absolute numbers of HY TCR-
positive cells in spleens. B, left, representative dotplots showing CD4 and 
CD8 expression on HY-negative splenocytes. Right, top, percentage and 
number of HY-negative CD4+ and CD8+ cells. Bottom, percentage and 
number of HY-negative CD44hi T cells. Graphs show the mean + SEM.  N = 
3 mice per genotype. Statistical significance was determined using the 
unpaired one-tailed Student‟s t-test. ***p < 0.001. 
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Figure 22. NF1-deficiency does not affect antigen-specific CD8+ T cell 
effector function in HY TCR-transgenic mice.  
Purified CD8+ T cells were stimulated with the indicated concentrations of 
HY peptide or CD3 and CD28 mAb for 48 hours. IFN- (top), Eomes (middle) 
and T-bet (bottom) expression were measured in HY TCR+ CD8+ T cells 
using flow cytometry. N = 2 mice per genotype. Statistical significance was 
determined using the unpaired one-tailed Student‟s t-test. *p < 0.05. 
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2.5. Discussion 
 
We have shown that NF1 acts in T cells during thymocyte development, as 
determined by disruptions in thymic developmental stages, most notably a partial 
block in the transition from DN3 to DN4. NF1 acts in thymocyte development in a 
haploinsufficient manner, as determined through investigation of mice with a 
heterozygous T cell-deficiency of NF1. NF1 may also affect positive selection of T 
cells as determined by an apparent partial block in the DP to CD8 SP transition that 
we observed in NF1-deficient HY TCR-transgenic mice. Further, T cell-specific NF1 
deficiency impacts peripheral T cell homeostasis, as determined by our observations 
of losses in the naïve CD4
+ 
and CD8
+
 T cell compartments in both NF1-deficient and 
NF1-heterozygous mice. However, NF1 appears to play a modest role in the 
regulation of T cell effector function, as we only observed moderate significant 
differences in effector cytokine or transcription factor expression in naïve CD8
+
 T 
cells upon TCR stimulation. Increases in secreted cytokine that we observed in NF1-
deficient T cell cultures are likely the result of higher frequencies of CD44
hi 
effector/memory cells in NF1-deficient T cell populations, due to the partial loss of 
naïve T cells. 
 
Disruptions in thymocyte development as a result of NF1 deletion were not 
particularly surprising. The role of Ras-MAPK signaling has been well established in 
thymocyte development. More recently, a related RasGAP, RASA1, was found to 
affect thymocyte positive selection and survival (32). NF1 may also affect positive 
selection in thymocytes, as observed in our studies with HY TCR-transgenic mice. 
69 
 
Curiously, in HY TCR-transgenic mice, NF1 appears to promote transition from DP 
to CD8 SP; RASA1 was reported to have the opposite effect on CD4 T cell positive 
selection on the AND TCR-transgenic background. NF1 and RASA1 apparently act 
at different stages of thymocyte development and on different developmental stages.  
 
Loss of peripheral naïve T cells has been previously reported in mice with a T cell-
specific deletion of RASA1, as well as in mice that express a constitutively active 
form of ERK2 (32, 85). For this reason, the homeostatic abnormalities that resulted in 
peripheral T cells losses in T cell KO and Het mice were not surprising. In RASA1-
deficient T cells, this loss of naïve T cells was attributed to dysregulated signaling 
downstream of the Il-7 receptor, as IL-7 is a critical promoter of peripheral T cell 
survival. However, we did not observe a similar lack of survival response to IL-7 in 
NF1-deficient T cells. It is possible that abnormal responses to other survival factors 
are the cause of reduced naïve T cell numbers. It is also possible that the moderate 
effects of NF1-deficiency on thymocyte development may affect peripheral T cell 
homeostasis at a greater level. Continued experiments with TCR transgenic mice are 
expected to provide insight into the effects of NF1-deficiency on clonal T cell 
populations. 
 
The finding that NF1-deficient mice were able to respond to Listeria monocytogenes 
infection more efficiently was interesting. Initially we hypothesized that NF1-
deficient T cells were more likely to become activated in response to TCR-mediated 
Ras signal transduction, and that perhaps NF1-deficient T cells would mount a 
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stronger proliferative response. However, in vitro experiments with T cells from 
uninfected animals demonstrated that NF1-deficient T cells do not mount an 
abnormal proliferative response, nor could we detect changes in ERK 
phosphorylation, which we would expect downstream of dysregulated Ras activation. 
Future experiments in which T cells from L. monocytogenes-infected mice were 
analyzed for effector responses may shed light on this phenomenon. 
 
The surprising findings in our L. monocytogenes experiment led us to wonder if NF1-
deficient T cells would demonstrate significantly greater effector function in vitro. 
We hypothesized that differences in function would become apparent over a longer 
course of activation, although analysis of previously activated CD4
+
 T cells failed to 
show a change in Ras-ERK signaling. In fact, we did observe increased effector 
cytokine secretion in longer-term cultures of both CD4
+
 and CD8
+
 T cells, although 
we conclude that this is due to a higher frequency of CD44
hi 
memory T cells in the 
NF1-deficient cultures that results from the loss of naïve cells. Flow cytometry 
analysis showed an increase in the frequency of cells expressing IFN- and Eomes in 
T cell KO CD8
+
 T cells in response to antibody-mediated TCR stimulation. However, 
we failed to observe increased an increase in the frequency of cytokine or 
transcription factor expression in a clonal CD8
+
 T cell population in response to 
stimulation with cognate antigen-MHC complex. The HY peptide used in the clonal 
antigen stimulation experiments is not a particularly strong effector peptide; perhaps 
our observations in polyclonal T cell cultures and in vivo are due to increased strength 
of signal received through the TCR. 
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Our findings with regards to cell numbers and proliferative capabilities are in 
contradiction to an earlier report in which liver or bone marrow cells from fetal nf1-
null homozygous mice were transplanted into RAG-deficient mice. In this model, the 
resulting NF1-deficient thymocytes and peripheral T cells were hyperproliferative, 
with a high constitutive level of Ras activation (86). This is in clear contrast to our 
observations that T cell-specific NF1 deficiency does not generally affect thymocyte 
numbers and that it negatively affects peripheral T cell numbers. A major caveat of 
the earlier report was that, although the recipient mice were deficient only in 
lymphocytes, NF1-deficiencies in hematopoietic cell populations have been widely 
reported to promote myeloproliferative disorders in mice and men (52, 54, 154, 170). 
NF1-deficient myeloid cells have also been reported to be hyperresponsive to 
cytokine stimulation, which may result in activation that would affect the T cell 
population indirectly. We believe that our model of T cell-specific deletion allows us 
to more accurately determine the effects of lineage-specific NF1 deficiency on 
thymocyte development and the maintenance of the T cell compartment. 
 
We are also aware that, overall, the effects of NF1 on the T cell compartment are 
moderate. We believe that this is likely due to the expression of multiple RasGAPs in 
T cells. Some redundancy of function is likely to be present as a result. NF1-deficient 
T cells, although they possess somewhat different developmental abnormalities in the 
thymus, behave much as RASA1-deficient T cells in the periphery. However, we do 
not expect that NF1 and RASA1 are each simply able to compensate for the loss of 
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the other; in initial experiments with mice bearing T cell-specific deletions of NF1 
and RASA1 concurrently, we did not observe greater abnormalities in thymocyte 
development or peripheral T cell homeostasis (data not shown). This indicates to us 
that likely another RasGAP is primarily responsible for the negative regulation of Ras 
in the T cell compartment. The RasGAP RASAL3 has been recently reported to be 
phosphorylated downstream of the TCR (171). Little is currently understood about 
RASAL3; it is known to be strongly expressed in the thymus and peripheral lymphoid 
organs (unpublished data) almost to the exclusion of expression in non-lymphoid 
tissue. Future investigation into the role of this protein in the T cell compartment will 
hopefully shed light on the mechanisms of negative regulation of Ras. 
 
In conclusion, we believe that we have demonstrated a significant role for NF1 in 
thymocyte development. Further, we have demonstrated that NF1 affects peripheral T 
cell homeostasis although we have yet to determine the mechanism by which this 
occurs. Finally, we have shown that NF1 deficiency promotes the immune response 
to an intracellular bacterial pathogen and enhances naïve CD8
+
 T cell effector 
responses, although the cellular mechanisms by which these occur are as yet 
undetermined. Future studies are expected to shed light on this phenomenon. 
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Chapter 3 
 
IL-4 acts as a potent stimulator of IFN expression in CD8+ T cells through 
STAT6-dependent and independent induction of Eomesodermin and T-bet 
 
3.1. Abstract 
CD8
+
 T cell synthesis of IFN- is an important component of the CD8+ T cell 
immune response. The cytokine IL-4 has been reported to promote CD8
+
 T cell 
activity in vivo, although whether IL-4 acts directly on CD8
+
 T cells or indirectly 
through action on another cell type is unclear. In short-term cultures of murine pan-T 
cells, we found that IL-4 was the principal cytokine responsible for driving IFN- 
synthesis by CD3/CD28-activated CD8
+ 
T cells. IL-4 was able to induce low levels of 
IFN-mRNA in CD8+ T cells even in the absence of CD3/CD28 engagement, 
although concomitant CD3/CD28 stimulation was necessary for IFN- secretion. IL-4 
induction of IFN- was explained by its ability to induce Eomesodermin and T-bet 
transcription factors whose expression was further increased by CD3/CD28. 
Expression of Eomesodermin, T-bet and IFN- induced by IL-4 was partially 
dependent upon activation of MAPK and PI3K but independent of the canonical IL-4-
activated transcription factor, STAT6. In contrast, expression of IFN- induced by IL-
4/CD3/CD28 stimulation showed additional dependency upon STAT6 which 
functions to increase expression of Eomesodermin specifically. These novel findings 
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point to a function for IL-4 as a direct regulator of IFN- expression in CD8+ T cells 
and reveal the molecular mechanisms involved (172).
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3.2. Introduction 
 
CD8
+
 T cells are the principal effector cells of the adaptive immune response directed 
toward intracellular pathogens. Initial activation of CD8
+
 T cells results from TCR 
and costimulatory receptor recognition of MHC class I-antigenic peptide complexes 
and costimulatory ligands respectively that are both displayed upon the surface of 
professional APC. Once activated, effector CD8
+
 T cells then target infected cells 
through TCR recognition of the same MHC class I-peptide complexes displayed on 
the target cell surface. Another important mechanism by which CD8
+
 T cells control 
intracellular infections is through synthesis of IFN- that has antiviral and 
macrophage-activating properties.  
 
In many, although not all types of infection, activation of CD8
+
 T cells and 
development of memory CD8
+
 T cells is additionally dependent upon signals 
provided by CD4
+
 T cells or other immune cell types (173-177). One important CD4
+
 
T cell-derived factor that promotes CD8
+
 T cell activation is the IL-2 cytokine (178). 
In addition, IL-4, classically studied as a regulator of CD4
+
 Th2 cell differentiation 
and B cell immunoglobulin class switching and differentiation (179, 180), has also 
been implicated as a helper factor for CD8
+
 T cell responses. In 
lymphochoriomeningitis virus and vaccinia virus infection models, mice that are 
double-deficient for IL-2 and IL-4 show a more severe impairment in an ability to 
generate specific CTL upon restimulation ex vivo compared to mice singly-deficient 
for IL-2 (181). In addition, in an influenza virus infection model, mice deficient in the 
IL-4R alpha receptor showed reduced CTL responses ex vivo (182). IL-4 has also 
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been shown to regulate CD8
+
 T cell responses in parasitic infection models. In 
Plasmodium yoelii mouse malaria, Leishmania Donovani and Schistosoma mansoni 
infection models, generation of IFN- expressing CD8+ T cells following ex vivo 
restimulation was profoundly reduced in IL-4-deficient animals (183-185). However, 
in each of these studies, it is unclear if IL-4 acts directly upon CD8
+
 T cells to 
regulate IFN- synthesis or cytotoxic activity or indirectly through action upon 
another cell type. Moreover, IL-4 has been shown to be required for the generation of 
memory CD8
+
 T cells which compared to naïve T cells synthesize much greater 
quantities of IFN- and cytotoxic effector molecules (186). Therefore, an apparent 
role for IL-4 in the induction of IFN- and cytoxicity as revealed upon ex vivo 
stimulation could reflect a role for this cytokine in induction of memory cell 
formation in vivo rather than its ability to directly regulate these responses per se. 
 
In the current studies we show that IL-4 acts as a direct regulator of CD8
+
 T cell 
function independent of its role as an inducer of CD8
+ 
T cell memory. The 
mechanism by which IL-4 induces expression of IFN- in CD8+ T cells was 
investigated in detail. IL-4 induces expression of Eomesodermin (Eomes) and T-bet 
transcription factors that activate transcription of the ifng gene. Coupling of the IL-4R 
to both transcription factors in part depends upon IL-4-mediated activation of the 
intracellular signaling enzymes, MAPK and PI3K. In addition, in the presence of 
concomitant TCR and costimulatory receptor stimulation, an important role for IL-4-
mediated STAT6 transcription factor activation in IFN- induction, specifically 
through induction of Eomes, was demonstrated.  
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3.3. Materials and methods 
 Mice 
C57BL/6 x 129 Sv mice were bred in the animal facility at the University of 
Michigan Medical School. C57BL/6, IL-4-deficient and STAT6-deficient (both on a 
C57BL/6 background) and BALB/c mice were purchased from the Jackson 
Laboratory. All mice were 2-3 months old at the time of experiments. All 
experiments were performed in compliance with University of Michigan guidelines 
and were approved by the University Committee on the Use and Care of Animals. 
 
Isolation and stimulation of peripheral T cells 
Pan-T cells or CD8
+
 T cell populations were prepared from pooled spleen and lymph 
node cell suspensions using MACS pan-T cell or CD8
+
 T cell negative selection kits 
(Miltenyi) respectively according to manufacturer‟s instructions. For isolation of 
NKT cell-depleted pan-T cells and CD44
lo 
CD8
+
 T cell populations, NK1.1 and CD44 
mAb (eBioScience) were used in conjunction with pan-T cell and CD8
+ 
T cell 
isolation kits respectively. Purity of negatively selected T cell populations was 
routinely determined by flow cytometric analysis.  
 
T cells were stimulated in wells of 96 well U-bottomed plates in RPMI 1640 
containing 10% FBS and antibiotics (2 x 10
5
 cells/200 ml/well). For CD3/CD28 mAb 
stimulation, wells were pre-coated with CD3 mAb (1 g/ml; eBioScience) and 
soluble CD28 mAb was included in the culture medium (1 g/ml; eBioScience). 
Neutralizing anti-IL-2 and anti-IL-4 mAb (BD Pharmingen) were added to wells at 1 
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g/ml. Recombinant murine IL-2 and IL-4 (R&D Systems) were added to wells at 
100 and 10 ng/ml respectively. PD98059 and wortmannin inhibitors (Calbiochem) 
were added to wells at 50 and 1 nM respectively. 
 
Flow cytometry 
Cells were harvested from wells and analyzed for cell surface expression of CD4, 
CD8, CD44, CD49b (DX5) and intracellular expression of IFN-, Eomes and T-bet 
by flow cytometry using respective fluorochrome-labeled mAb (BD Pharmingen 
except CD49b, Eomes and T-bet mAb which were purchased from eBioScience).  
CD1d--GalCer tetramer used for detection of NKT cells was purchased from the 
NIH Tetramer Core Facility. For intracellular staining, harvested cells were treated 
with PMA and ionomycin (50 ng/ml and 1.5 M respectively; Sigma Aldrich) for 5 h 
with addition of brefeldin A (1:1000 dilution of stock; BD Biosciences) for the last 4 
h of culture. Cells were then surface stained prior to fixation and permeabilization and 
intracellular staining. Cellular data was collected on a FACSCanto flow cytometer 
equipped with FACSDiva software (BD Biosciences). 
 
ELISA 
Concentrations of IFN- in well supernatants were determined with the use of a Duo-
set ELISA kit (R&D Systems). To assay Granzyme B secretion, stimulated T cells 
were harvested and restimulated in CD3 mAb coated wells as above. Granzyme B 
concentrations in well supernatants were then determined with the use of a Granzyme 
B Duo-set ELISA kit (R&D Systems).  
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Real time RT-PCR 
RNA was isolated from stimulated CD8+ T cells using Trizol (Invitrogen) and 
reverse transcribed using SuperScript reverse transcriptase (Invitrogen). Real time 
PCR was performed using established IFN- and -actin Taqman primer/probe sets in 
a 7500 Fast Lightcycler (Applied Biosystems). Fold change in IFN- mRNA 
expression relative to unstimulated CD8
+ 
T cells was determined as described (187). 
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3.4. Results 
 
A major role for IL-4 in induction of IFN- expression in CD8+ T cells 
 
As shown by intracellular staining, stimulation of pan-T cells with CD3 mAb 
(directed to the TCR complex) and mAb against the CD28 costimulatory receptor for 
48 h in vitro results in CD8
+
 T cell expression of IFN- (Fig. 23A). Substantial 
induction of IFN- is observed in both CD44lo naïve and CD44hi memory phenotype 
CD8
+
 T cells in these cultures. In contrast, purified CD8
+
 T cells synthesize little 
IFN- in response to the same stimulus, at least as detected by intracellular staining 
(Fig. 23A). Thus, other T cells provide help to CD8
+
 T cells in order for them to 
synthesize IFN-.  
 
IL-2 is considered an important helper factor for CD8
+
 T cell responses (178). To 
address this, we included a neutralizing anti-IL-2 antibody in pan-T cell cultures. 
However, blockade of IL-2 only partially inhibited the ability of CD8
+
 T cells to 
synthesize IFN-in pan-T cell cultures (Fig. 23B). Therefore, we examined the effect 
of blocking antibodies against other cytokines whose receptors share the same 
common gamma chain subunit with the IL-2R (70, 188). Of these, antibodies against 
IL-7, IL-9, IL-15 and IL-21 had no effect upon CD8
+
 T cell IFN- synthesis (data not 
shown). In contrast, a neutralizing antibody against IL-4 profoundly blocked CD8
+
 T 
cell IFN- expression, particularly in CD44lo CD8+ T cells (Fig. 23B). Furthermore, 
combined blockade of IL-2 and IL-4 essentially abrogated the ability of both CD44
lo
 
and CD44
hi 
CD8
+
 T cells to synthesize IFN-(Fig. 23B).  
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Based on these findings, we next examined if addition of IL-4 to cultures of purified 
CD8
+
 T cells could restore IFN- expression in response to CD3/CD28 mAb 
stimulation. In comparison with IL-2, IL-4 was found to be a potent inducer of IFN- 
expression in CD3/CD28 mAb-stimulated CD8
+
 T cells, particularly in the CD44
lo
 
subset (Fig. 23C).  
 
To confirm a predominant role for IL-4 in induction of CD8
+
 T cell synthesis of IFN-
, we examined IFN- expression in CD8+ T cells from IL-4-deficient mice. 
Consistent with results of antibody blocking studies, CD8
+
 T cells in CD3/CD28-
stimulated pan-T cell cultures from IL-4-deficient mice synthesized reduced levels of 
IFN- in comparison to CD8+ T cells from C57BL/6 control mice (Fig. 24). Again, 
the dependency upon IL-4 was most apparent in CD44
lo
 CD8
+
 T cells. A major role 
for IL-4 in the induction of IFN-synthesis in CD44lo CD8+ T cells was also 
demonstrated in mouse strains other than C57BL/6 or 129 Sv, e.g. BALB/c (Fig. 25).  
 
NKT cells are known to rapidly synthesize IL-4 in response to TCR engagement 
(189). Therefore, since NKT cells would be present in pan-T cell cultures, we asked if 
they were required for CD8
+
 T cell synthesis of IFN- through provision of IL-4. For 
this purpose, we performed additional negative selection for the NK1.1 marker that is 
expressed upon the majority of mature NKT cells in the peripheral immune system of 
mice (Fig. 26)(190). As shown by staining with CD1d--GalCer tetramers and 
antibodies against the DX5 marker that is also expressed by NKT cells(190), NK1.1 
negative selection was only partially effective at depleting NKT cells in C57BL/6 x 
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129 Sv mice. Furthermore, NK1.1 depletion did not affect CD8
+
 T cell synthesis of 
IFN- in response to CD3/CD28 mAb stimulation in this strain. By contrast, the same 
NK1.1 negative selection procedure resulted in depletion of the vast majority of NKT 
cells in C57BL/6 mice, which could potentially be explained by differences in the 
level of expression of NK1.1 between the two strains. More importantly, in C57BL/6 
mice, NKT cell depletion resulted in much reduced IFN- synthesis by CD44lo CD8+ 
T cells following stimulation with CD3/CD28 mAb. In addition, the residual IFN- 
response of these cells was not inhibited with an anti-IL-4 mAb. These results, 
therefore, indicate that NKT cells are the principal source of IL-4 that drives CD8
+
 T 
cell synthesis of IFN- at least in the CD44lo subset. 
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Figure 23.  Role of IL-2 and IL-4 in induction of IFN- expression in 
CD8+ T cells.  
Experiments were performed with T cells from littermate C57BL/6 x 129 Sv (A-C) or 
C57BL/6 (D) mice. A, Pan-T cells or purified CD8+ T cells were stimulated or not 
with CD3 and CD28 mAb. After 48 h, expression of IFN- upon CD44lo and CD44hi 
CD8+ T cells was determined by flow cytometry. At left are shown representative 
two color flow cytometry plots of CD44 versus IFN- staining. Numbers indicate 
percentage of CD8+ T cells in each quadrant. Bar charts at right show the mean 
percentage of IFN-positive cells + 1 SEM for CD44lo and CD44hi CD8+ T cells 
determined in repeat experiments (n=5 mice). B, Pan-T cells were stimulated as in 
(A) in the presence or absence of neutralizing anti-IL-2 and/or anti-IL-4 antibodies. 
Representative flow cytometry plots of CD44 versus IFN- staining are shown at left. 
Bar charts show mean percentage of IFN-positive cells + 1 SEM for CD44lo and 
CD44
hi 
CD8+ T cells under each stimulation condition determined in repeat 
experiments (n=5 mice). C, Purified CD8+ T cells were stimulated as in (A) in the 
presence or absence of recombinant IL-2 or IL-4. Representative flow cytometry plots 
of CD44 versus IFN- staining are shown at left. Bar graphs at right show the mean 
percentage of IFN-positive cells + 1 SEM for CD44lo and CD44hi CD8+ T cells 
under the indicated stimulation conditions determined in repeat experiments (n=4 
mice). Statistical significance was determined using the unpaired Student‟s t-test. *p 
< 0.05, **p < 0.01, ***p < 0.001. 
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Figure 24.  IFN- expression in IL-4-deficient T cells.  
Pan-T cells from C57BL/6 IL-4-deficient (IL-4 KO) and wild type control 
C57BL/6 mice were stimulated or not with CD3 and CD28 mAb in the 
presence or absence of neutralizing anti-IL-2 and/or anti-IL-4 mAb. 
Expression of IFN- upon CD44lo and CD44hi CD8+ T cells was determined 
by flow cytometry after 48 h of culture. At top are shown representative flow 
cytometry plots of CD44 versus IFN- staining. Bar graphs show the mean 
percentage of IFN- positive cells + 1 SEM for CD44lo and CD44hi CD8+ T 
cells for each mouse genotype and condition of stimulation as determined in 
repeat experiments (n=5 mice each genotype). Statistical significance was 
determined using the paired Student‟s t-test. *p < 0.05, **p < 0.01. 
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Figure 25.  Role of IL-4 in CD8+ T cell synthesis of IFN- in BALB/c mice.  
Pan-T cells from wild type C57BL/6 and BALB/c mice were stimulated or not 
with CD3 and CD28 mAb in the presence or absence of neutralizing anti-IL-4 
mAb. After 48 h, expression of IFN- upon CD44lo and CD44hi CD8+ T cells 
was determined by flow cytometry. Bar graphs show the mean percentage of 
IFN- positive cells + 1 SEM for CD44lo and CD44hi CD8+ T cells for each 
mouse genotype and condition of stimulation as determined in repeat 
experiments (n=5 mice each genotype). Statistical significance was determined 
using the paired Student‟s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 26. Cellular source of IL-4 for IFN- induction in CD8+ T cells.  
A, Pan T cells were depleted or not of NKT cells by negative selection using 
an NK1.1 mAb. Shown are two-color plots of DX5 mAb (CD49b) and CD1d-
GalCer tetramer staining from three mice of each genotype. B, Pan-T cells 
or NKT cell-depleted pan-T cells from wild type C57BL/6 x 129 Sv mice or 
C57BL/6 mice (as in A) were stimulated with CD3 and CD28 mAb in the 
presence or absence of a neutralizing anti-IL-4 mAb. After 48 h, expression of 
IFN- upon CD44lo and CD44hi CD8+ T cell subsets was determined by flow 
cytometry. Bar graphs show the mean percentage of IFN- positive cells + 1 
SEM for CD44
lo
 and CD44
hi 
CD8+ T cells for each mouse genotype as 
determined in repeat experiments (n=5 mice each genotype). Statistical 
significance was determined using the two sample Student‟s t-test. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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IL-4 induces the expression of intracellular IFN- in CD8+ T cells in the absence of 
TCR and costimulatory receptor engagement 
As a negative control in experiments, we examined the influence of IL-4 alone upon 
CD8
+
 T cell expression of IFN-. Surprisingly, as detected by intracellular staining, 
IL-4 alone induced similar levels of IFN- expression in CD44lo and CD44hi CD8+ T 
cells to that observed when T cells were stimulated with IL-4 plus CD3 and CD28 
mAb (Fig. 27A). However, as determined by ELISA of well supernatants, none of the 
IFN- induced by IL-4 in the absence of CD3/CD28 engagement was secreted from 
cells but instead remained intracellular (Fig. 27B). Thus, CD3/CD28 engagement is 
necessary for the secretion of IL-4-induced IFN- in CD8+ T cells. With this 
knowledge, we considered that IL-4 plus CD3/CD28 engagement might in fact induce 
much higher levels of IFN- expression in CD8+ T cells compared to IL-4 stimulation 
alone. However, the difference would not be detected by intracellular staining since 
concurrent CD3/CD28 stimulation would result in continual release of de novo 
synthesized IFN- whereas in IL-4 alone stimulated CD8+ T cells the de novo 
synthesized IFN- would accumulate. To confirm this possibility, we examined IFN- 
mRNA levels in CD8
+
 T cells by real time RT-PCR. As predicted, stimulation of 
CD44
lo
 CD8
+
 T cells with the combination of IL-4 plus CD3/CD28 mAb resulted in 
much higher levels of IFN-mRNA expression than stimulation with IL-4 alone (Fig. 
27C). Thus, although IL-4 alone is able to induce IFN- expression in CD8+ T cells, 
IL-4 is in fact a relatively weak inducer of IFN- in the absence of concurrent 
CD3/CD28 stimulation. In addition, stimulation of CD8
+ 
T cells with IL-4 alone does 
not result in IFN- secretion. 
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Figure 27. IL-4 induced synthesis of IFN- in CD8+ T cells with and 
without concurrent CD3/CD28 stimulation.  
All experiments were performed with T cells from C57BL/6 x 129 Sv mice. A, 
Purified CD8+ T cells were stimulated or not with IL-4 and/or CD3 and CD28 
mAb for 48 h. Expression of IFN- in CD44lo and CD44hi CD8+ T cells was 
determined by flow cytometry. At left are shown representative flow 
cytometric plots of CD44 vs IFN- staining. Bar graph at right shows the mean 
percentage of IFN- positive cells + 1 SEM for CD44lo and CD44hi CD8+ T 
cells under different stimulation conditions as determined in repeat 
experiments (n=7 mice). B, Purified CD8+ T cells were stimulated as in (A). 
Concentrations of IFN-in well supernatants were determined by ELISA. 
Shown is the mean concentration of IFN- + 1 SEM for each stimulation 
condition as determined repeat experiments (n=4 mice). N.D., not detectable. 
C, Purified CD8+ CD44
lo
 T cells were stimulated or not with IL-4 and/or CD3 
and CD28 mAb for 6 h. Relative expression levels of IFN- mRNA were 
determined by real time RT-PCR. Results are expressed as fold change in IFN-
 expression compared to non-stimulated T cells. Similar results were obtained 
in a repeat experiment. In (A) and (B) statistical significance was determined 
using the paired Student‟s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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IL-4 promotes the cytotoxic function of CD8+ T cells but is not required for CD8+ T 
cell proliferation 
We further asked if IL-4 was necessary for the acquisition of CD8
+
 T cell cytotoxic 
function in vitro. Efficiency of CTL priming was measured by expression of the 
lysosomal marker CD107a that is induced in CD8
+
 T cells during the acquisition of 
cytotoxic function (191). In wild type mice, CD3/CD28 mAb stimulation of pan-T 
cells resulted in expression of CD107a in CD44
hi
 CD8
+
 T cells that was blocked by 
approximately 50 percent by anti-IL-2 or anti-IL-4 mAb and completely by both 
types of mAb when included in priming cultures (Fig. 28A). We also examined 
secretion of the cytotoxic effector molecule, Granzyme B, by ELISA. Blockade of 
either IL-2 or IL-4 during CD3/CD28 mAb-induced priming of wild type pan-T cells, 
or intrinsic IL-4 deficiency, was sufficient to almost completely block the synthesis 
and secretion of Granzyme B by CD8
+
 T cells (Fig. 28B). Consistent with these 
results, in IL-4-deficient mice, induction of CD107a surface expression in CD8
+
 T 
cells was substantially reduced (Fig. 28A). IL-4 also induced expression of CD107a 
in purified CD44
lo
 and CD44
hi
 CD8
+
 T cells, albeit not to the levels observed with 
concurrent CD3 and CD28 stimulation (Fig. 28C).  
 
We also asked if IL-4 played a role in the induction of CD8
+
 T cell proliferation in 
CD3/CD28-stimulated pan-T cell cultures by monitoring CD8
+
 T cell dilution of 
CFSE label by flow cytometry. In these experiments, blocking IL-2 and IL-4 mAb, 
when used either alone or together, did not affect the CD8
+
 T cell proliferative 
response (Fig. 29). 
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Figure 28. Role of IL-4 in induction of CD8+ T cell cytotoxic function. 
 A, Pan-T cells from IL-4-deficient and wild type control C57BL/6 mice were 
stimulated or not with anti-CD3 and CD28 mAb in the presence or absence of 
neutralizing anti-IL-2 and/or anti-IL-4 mAb. After 72 h, cells were 
restimulated in CD3 mAb coated (1 mg/well) wells (1 x 10
5
 cells/well) in 
medium containing labeled CD107a mAb before staining for additional cell 
surface markers. Expression of cell surface CD107a upon CD8+ CD44
lo
 and 
CD44
hi
 T cell subsets was determined by flow cytometry. At left are shown 
representative flow cytometry plots of CD44 and CD107a staining. The bar 
graph at right shows the mean percentage of CD107a-positive cells + 1 SEM 
among CD8+ CD44
hi
 cells under different conditions of stimulation in the two 
strains of mice as determined in repeat experiments (n=4 mice each genotype). 
B, Purified CD8+ T cells from C57BL/6 mice were stimulated or not with 
CD3 and CD28 mAb and/or IL-4 as in (A) and expression of CD44 and 
CD107a was determined by flow cytometry.  At left are shown representative 
flow cytometry plots of CD44 and CD107a staining. Bar graphs at right show 
the mean percentage of CD107a-positive cells + 1 SEM for CD44
lo
 and 
CD44
hi 
CD8+ T cells under different stimulation conditions as determined in 
repeat experiments (n=3 mice). C, Pan-T cells from IL-4-deficient mice and 
wild type control C57BL/6 mice were stimulated as in (A). After 4 h 
restimulation, concentrations of Granzyme B in well supernatants were 
determined by ELISA. Shown is the mean concentration of Granzyme B +1 
SEM for the different stimulation conditions and mouse genotypes as 
determined in repeat experiments (n=4 mice each genotype). Statistical 
significance was determined using the paired Student‟s t-test. *p < 0.05, **p < 
0.01, ***p < 0.001.  
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Figure 29. Role of IL-4 in CD8+ T cell proliferation in vitro. 
CFSE-labeled pan-T cells from C57BL/6 mice were stimulated or not with 
anti-CD3 and CD28 mAb in the presence or absence of neutralizing anti-IL-2 
and/or anti-IL-4 mAb. After 96 h, CFSE fluorescence of CD8+ T cells was 
determined by flow cytometry. At left are shown representative flow 
cytometry plots of CFSE fluorescence versus CD44 staining. The bar graph at 
right shows the mean percentage of live CD8+ T cells + 1 SEM that have 
undergone the indicated number of divisions under the different conditions of 
stimulation as determined in repeat experiments (n=4 mice). Statistical 
significance was determined using the paired Student‟s t-test. 
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IL-4 induces the expression of Eomes and T-bet transcription factors in CD8
+
 T cells 
Expression of IFN- in CD8+ T cells is controlled by Eomes and T-bet transcription 
factors (115, 192). Therefore, we asked if IL-4 induced the expression of either 
transcription factor in CD8
+
 T cells that would account for IFN- gene transcription. 
First, we examined if expression of Eomes and T-bet in CD8
+
 T cells in CD3/CD28 
mAb-stimulated pan-T cell cultures was dependent upon IL-4. As shown, CD3/CD28 
mAb stimulation of pan-T cells resulted in an induction of Eomes and T-bet 
expression in CD8+ T cells (Fig. 30, 31). In CD44
lo 
T cells, stronger induction of 
Eomes compared to T-bet was noted, whereas in CD44
hi
 subpopulations these 
transcription factors were induced to a similar degree. Significantly, expression of 
both of these transcription factors in both CD8
+
 T cell subpopulations was inhibited 
by a blocking anti-IL-4 mAb (Fig. 30, 31).  
 
We next examined if IL-4 could induce expression of either transcription factor in 
purified CD8
+
 T cells. IL-4 alone induced expression of Eomes and T-bet in CD44
lo 
and CD44
hi
 CD8
+
 T cell subpopulations, although in CD44
lo
 cells, Eomes was more 
strongly induced, consistent with findings with pan-T cells (Fig. 30A,B). 
Furthermore, the combination of IL-4 plus CD3/CD28 mAb resulted in increased 
expression of both transcription factors in CD8
+
 T cells (Eomes in CD44
lo 
and CD44
hi
 
cells and T-bet in CD44
hi
 cells only), consistent with increased levels of IFN- 
mRNA (Fig. 27 C; Fig. 30B, 31B). We conclude that IL-4 drives IFN- expression in 
CD8
+
 T cells through induction of the expression of Eomes and T-bet. 
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Figure 30. IL-4-mediated induction of Eomes and T-bet transcription 
factors in CD8+ T cells.  
Pan-T cells (A) or purified CD8+ T cells (B) from C57BL/6 x 129 Sv mice 
were stimulated or not with CD3 and CD28 mAb in the presence or absence of 
a neutralizing IL-4 mAb (A) or with or without IL-4 or with IL-4 alone (B) as 
indicated. After 48 h, expression of CD44 and Eomes upon CD8+ T cells was 
determined by flow cytometry. At left are shown representative flow 
cytometry plots of CD44 versus transcription factor staining. Bar graphs at 
right shown the mean percentage of transcription factor positive cells + 1 SEM 
within CD44
lo 
and CD44
hi 
CD8+ T cell populations under the different 
stimulation conditions as determined in repeat experiments. N = 5 for each 
genotype. Statistical significance was determined using the unpaired two-
tailed Student‟s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 31. IL-4-mediated induction of T-bet transcription factor in CD8+ 
T cells.  
Pan-T cells (A) or purified CD8+ T cells (B) from C57BL/6 x 129 Sv mice 
were stimulated or not with CD3 and CD28 mAb in the presence or absence of 
a neutralizing IL-4 mAb (A) or with or without IL-4 or with IL-4 alone (B) as 
indicated. After 48 h, expression of CD44 T-bet upon CD8+ T cells was 
determined by flow cytometry. At left are shown representative flow 
cytometry plots of CD44 versus transcription factor staining. Bar graphs at 
right shown the mean percentage of transcription factor positive cells + 1 SEM 
within CD44
lo 
and CD44
hi 
CD8+ T cell populations under the different 
stimulation conditions as determined in repeat experiments. N = 4 for each 
genotype. Statistical significance was determined using the unpaired two-
tailed Student‟s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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STAT6 promotes IFN- expression in CD8+ T cells induced by the combination of 
IL-4 and CD3 plus CD28 mAb stimulation 
IL-4 signal transduction proceeds through the JAK-STAT pathway (193, 194). 
Binding of IL-4 to the IL-4R results in activation of receptor-associated JAK protein 
tyrosine kinases, which phosphorylate the IL-4R leading to recruitment of the STAT6 
transcription factor. JAK-mediated phosphorylation of STAT6 then promotes STAT6 
dimerization and nuclear translocation and activation of gene transcription programs. 
Given the established role of STAT6 in the IL-4 signal transduction pathway, we 
examined if this transcription factor was necessary for IL-4 induced expression of 
IFN-. To this end, we examined the ability of IL-4 to induce expression of IFN- in 
purified CD8
+
 T cells from STAT6-deficient mice. Surprisingly, when stimulated 
with IL-4 alone, loss of STAT6 did not impact upon the ability of CD8
+
 T cells to 
synthesize IFN- (Fig. 32A). In contrast, loss of STAT6 did result in reduced levels of 
IFN- expression in CD44lo CD8+ and CD44hi CD8+ T cells following stimulation 
with the combination of IL-4 and CD3/CD28 mAb (Fig. 32A). Therefore, stimulation 
of CD8
+ 
T cells with IL-4 plus CD3/CD28 mAb appears to license STAT6 
involvement in a signaling pathway that is associated with much increased levels of 
IFN-gene transcription (Fig. 27C). 
 
We further examined if STAT6 was necessary for IL-4 induced expression of Eomes 
and T-bet in CD8
+ 
T cells. Loss of STAT6 did not affect expression of Eomes or T-
bet in CD8
+
 T cells that were stimulated with IL-4 alone (Fig. 32B and C). However, 
as with IFN- induction, loss of STAT6 did result in reduced levels of expression of 
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Eomes in CD44
lo
 CD8
+
 T cells following stimulation with IL-4 plus CD3 and CD28 
mAb (Fig. 32B). Expression of T-bet was not affected by loss of STAT6 in CD8
+
 T 
cells following stimulation with IL-4 plus CD3 and CD28 mAb (Fig. 32C). From 
these findings we conclude that STAT6 functions to increase IFN- expression in IL-
4 plus CD3/CD28 mAb-stimulated CD8
+
 T cells primarily through increasing the 
expression of Eomes. 
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Figure 32. Role of STAT6 in IL-4-mediated induction of IFN- expression 
in CD8+ T cells.  
Purified CD8+ T cells from STAT6-deficient (STAT6 KO) or wild type 
C57BL/6 control mice were stimulated or not with CD3 and CD28 mAb 
and/or IL-4. After 48 h, expression of IFN- Eomes and T-bet (B) within 
CD44
lo
 and CD44
hi
 CD8+ T cell populations was determined by flow 
cytometry. Bar graphs show the mean percentage of IFN-or transcription 
factor-positive cells + 1 SEM for each condition of stimulation and mouse 
strain as determined in repeat experiments (n= at least 3 mice each genotype). 
Statistical significance was determined using the paired Student‟s t-test. *p < 
0.05. 
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IL-4 induction of IFN- expression in CD8+ T cells is partially dependent upon 
activation of MAPK and PI3K  
JAK-mediated phosphorylation of the IL-4R also leads to recruitment of the insulin 
receptor substrate adapter proteins that couple the IL-4R to activation of MAPK and 
PI3K (193-195). Furthermore, MAPK and PI3K are activated upon TCR and CD28 
engagement and are essential for a number of different types of T cell response (196, 
197). Therefore, we asked if MAPK and PI3K activation are necessary for IL-4-
induced CD8
+
 T cell expression of IFN-. For this purpose, purified CD8+ T cells 
were stimulated with IL-4 and/or CD3 and CD28 mAb in the presence or absence of 
the MAPK inhibitor, PD98059, or the PI3K inhibitor, wortmannin. PD98059 and 
wortmannin both partially inhibited CD8
+
 T cell expression of IFN- induced by IL-4 
alone and IL-4 plus CD3/CD28 mAb (Fig. 33A and B). Furthermore, this was 
associated with partial inhibition of expression of Eomes and T-bet for both types of 
induced response (Fig. 33C and D). Therefore, MAPK and PI3K promote IL-4 and 
IL-4 plus CD23/CD28-induced IFN- expression in CD8+ T cells by increasing the 
expression of Eomes and T-bet. 
 
We additionally examined the effect of combined MAPK and PI3K inhibition and 
STAT6 loss upon IL-4 plus CD3/CD28-induced IFN- secretion in CD8+ T cells (Fig. 
33E). Pair-wise combination of inhibitors and STAT6 loss resulted in further 
reduction of IFN- secretion compared to single inhibitors or STAT6 loss alone. 
Furthermore, combination of MAPK and PI3K inhibitors with STAT6 loss resulted in 
a complete blockade of the CD8
+
 T cell IFN- response. 
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Figure 33. Roles of ERK and PI3K activation in IL-4-mediated induction 
of IFN- expression in CD8+ T cells.  
Purified CD8+ T cells from C57BL/6 mice were stimulated or not with CD3 and 
CD28 mAb and/or IL-4 in the presence or absence of the ERK inhibitor PD98059 
(A,C) or the PI3K inhibitor wortmannin (B,D). After 48 h, expression of IFN- 
Eomes (C,D) and T-bet (C,D) within CD44
lo
 and CD44
hi
 CD8+ T cell populations 
was determined by flow cytometry. Bar graphs show the mean percentage of IFN-or 
transcription factor-positive cells + 1 SEM for each condition of stimulation as 
determined in repeat experiments (n= at least 3 mice each genotype). Statistical 
significance was determined using the paired Student‟s t-test. (E) Purified CD8+ T 
cells from STAT6-deficient or wild type C57BL/6 control mice were stimulated or 
not as in (A-D). After 48 h, the concentration of IFN-in well supernatants was 
determined by ELISA. Shown is the mean concentration of IFN- + 1 SEM for each 
condition of stimulation as determined in repeat experiments (n=3). Statistical 
significance was determined using the two sample Student‟s t-test. *p < 0.05, **p < 
0.01, ***p < 0.001. 
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3.5. Discussion 
We show here that IL-4 acts as a potent stimulator of IFN- synthesis and cytotoxic 
activity in CD8
+
 T cells. These functions for IL-4 cannot be explained on the basis of 
any role for IL-4 in CD8
+
 T cell memory development or proliferation. Importantly, 
therefore, findings expand upon previous studies and show that IL-4 activates CD8
+
 T 
cell IFN- synthesis and cytotoxic effector function directly. 
 
Regarding the mechanism by which IL-4 induces expression of IFN- in CD8+ T 
cells, interestingly, some induction of IFN- was observed when CD8+ T cells were 
stimulated with IL-4 alone in the absence of TCR and costimulatory receptor 
engagement. However, the IFN- synthesized upon IL-4 stimulation alone was not 
secreted from cells but was instead retained intracellularly. Therefore, IL-4 produced 
in the course of an immune response would not trigger IFN- secretion from 
bystander antigen non-specific CD8
+
 T cells unless their TCR and costimulatory 
receptors were also engaged. If IL-4 alone-induced IFN- synthesis in CD8+ T cells 
has a physiological purpose, one possibility is that it serves to amplify a TCR/CD28 
plus IL-4 induced IFN- response of antigen specific CD8+ T cells. 
 
The role of TCR/CD28 engagement upon CD8
+
 T cells in induction of IFN- 
secretion is not limited to an ability to stimulate release of IFN-. Thus, TCR and 
CD28 signals synergize with IL-4 signals to induce much higher levels of IFN- gene 
transcription. This is associated with increased expression of Eomes and T-bet 
transcription factors that are known activators of IFN- gene transcription in CD8+ T 
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cells (192). Eomes and T-bet also induce the expression of genes that mediate CTL 
lysis of target cells (192). Therefore, an ability of IL-4 with and without TCR/CD28 
engagement to induce both transcription factors in CD8+ T cells would also account 
for the role of this cytokine in the acquisition of cytotoxic effector function.  
 
IL-4-alone and IL-4 plus TCR/CD28-induced CD8
+ 
T cell IFN- synthesis was 
partially dependent upon activation of MAPK and PI3K. This could be accounted for 
on the basis that both signaling intermediates are necessary for full induction of 
Eomes and T-bet expression. Exactly how MAPK and PI3K promote Eomes and T-
bet expression in CD8
+
 T cells is unknown at present. However, MAPK and PI3K 
participate in signaling pathways that culminate in the activation of transcription 
factors such as activator protein 1 and nuclear factor kappa-B that have the potential 
to activate transcription of the Eomes and T-bet genes directly. 
 
STAT6 was not required for CD8
+ 
T cell IFN- synthesis induced by IL-4 alone but 
did promote IFN- synthesis in response to IL-4 plus TCR/CD28 engagement. 
However, the magnitude and kinetics of STAT6 activation in CD8
+
 T cells as 
detected by phospho-STAT6 western blotting was comparable following IL-4 alone 
or IL-4 plus TCR/CD28 activation (data not shown). Therefore, participation of 
STAT6 specifically upon additional TCR/CD28 engagement cannot be explained by 
increased activation of this transcription factor. Instead, TCR/CD28 triggering must 
act to license STAT6 involvement in the IFN- response through an as yet 
undetermined mechanism. Whatever this mechanism, STAT6 appears to increase 
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IFN- synthesis through increased expression of Eomes but not T-bet. Potentially, this 
specificity could be accounted for by an ability of STAT6 to activate transcription of 
the Eomes gene directly. 
 
The discovery that IL-4 promotes the expression of Eomes in naive CD8
+
 T cells is 
exciting in light of recent findings that state the critical role of Eomes in the 
promotion and maintenance of memory CD8
+
 T cell populations. Eomes-deficient 
CD8+ T cells have been reported as defective in establishing central memory cell 
populations in vivo (115). In addition, IL-4 is required for the development of a 
recently described population of innate CD8
+
 T cells in mice with a memory-like 
phenotype and constitutive expression of Eomes (198). IL-4 has also been shown 
been shown to promote memory development in adaptive CD8
+
 T cells in vivo, as 
well as their survival and proliferation (186, 199, 200). With regards to memory 
development, in the current studies we also found that blockade of IL-4 in CD3/28-
mAb stimulated pan-T cell cultures or addition of IL-4 to CD3/CD28 mAb-stimulated 
purified CD8
+
 T cells inhibited or promoted the generation of CD44
hi 
memory 
phenotype CD8
+
 T cells respectively (data not shown). Potentially, therefore, the role 
of IL-4 in CD8
+
 T cell IFN- expression might be explained by increased generation 
of memory phenotype CD8
+
 T cells and that memory CD8
+
 T cells intrinsically have 
an increased propensity to synthesize this cytokine in comparison with naïve CD8
+
 T 
cells. However, this possibility can be ruled out since IL-4 was shown to induce high 
levels of expression of IFN- in CD44lo naïve CD8+ T cells. In addition, IL-4 was 
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generally shown to induce higher levels of IFN- expression in CD44hi memory CD8+ 
T cells compared to memory CD8
+
 T cells deprived of this cytokine.  
 
In conclusion, we have identified IL-4 as a major direct inducer of IFN- expression 
in CD8
+
 T cells and have dissected the mechanisms involved. In concert with the 
TCR and costimulatory receptors, IL-4 induces expression of Eomes and T-bet and de 
novo transcription of the IFN-gene. Induction of both transcription factors is 
partially dependent upon activation of MAPK and PI3K enzymes in CD8
+
 T cells. 
However, only expression of Eomes is regulated by the STAT6 transcription factor. 
Altogether, these studies illuminate an important molecular mechanism involved in 
the control of CD8
+
 T cell immunity. 
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Chapter 4 
 
Synergistic interactions of the RasGAPs RASA1 and neurofibromin in the 
initiation of thymic lymphomas in mice 
 
 
 
4.1. Abstract 
The RasGAPs RASA1 and NF1 are negative regulators of Ras signaling in many cell 
types from embryonic development through the lifetime of the organism. Loss of NF1 
alone or with one allele of RASA1 largely predisposes mice to myeloid leukemia, 
similar to that which is observed in previously reported deletion models of NF1. We 
report for the first time the concomitant induced systemic deletion of RASA1 and 
NF1 in mice. There is little evidence that double-deficient mice possess 
characteristics reported in induced systemic single-deletion mice. Instead, a 
substantial subset of mice develop thymic lymphoma that resembles reported T-cell 
acute lymphoblastic lymphoma, in which lymphoid organs are seeded by an immature 
CD4
+
CD8
+
  population that originates in the thymus. A majority of these tumors are 
positive for activating Notch1 mutations, a further characteristic of T- cell acute 
lymphoblastic lymphoma (T-ALL). We believe that these novel findings are 
important in the study of RasGAP function in adult animals as well as in the studies 
of overlapping and non-redundant function of multiple RasGAPs within a given cell 
type.
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4.2. Introduction 
 
Negative regulation of the Ras signaling pathway is essential to the maintenance of 
cell and tissue homeostasis. Although activation of the Ras GTPase is a central 
component of many cell surface receptor pathways that transmit signals to the nucleus 
that promote cellular survival and growth, unchecked Ras signaling leads to negative 
consequences. Ras is considered an oncogene, as its dysregulation is regarded as 
causative in many human tumors (201).  
 
Ras activity is known to be negatively regulated by a family of proteins known as Ras 
GTPase-activating proteins (RasGAPs). These proteins share a catalytic GAP 
domain, which facilitates the cleavage of the -phosphate from Ras-bound GTP, thus 
rendering Ras inactive (36, 202, 203). As these proteins are critical to normal cell 
function, it is perhaps not surprising that there are often multiple RasGAPs expressed 
in a given cell type (132). This overlap of expression has presented many challenges 
in our understanding of the roles of each individual RasGAP as well as of potential 
synergistic and antagonistic interactions between RasGAP family members. 
 
The RasGAP neurofibromin (NF1) has been quite well studied in both mouse and 
man. NF1 is named for the human disease neurofibromatosis type 1, which is 
considered an autosomal-dominant disorder (204). The phenotypic indications
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of NF1 are caused by heterozygous loss-of-function or truncation mutations in the 
gene Nf1. Unchecked cellular growth is evident in the development of nerve sheath 
tumors, or neurofibromas, that are characteristic of neurofibromatosis type 1 (50, 
142). Although the majority of these neurofibromas are benign, patients with NF1 are 
predisposed to malignant nerve sheath tumors as well as myeloid leukocyte tumors 
(52, 54, 142, 154, 155, 205). Neurofibromatosis type 1 is also characterized by 
dysregulated cardiovascular development as well as neural defects, possibly due to 
non-redundant Ras regulatory functions in these tissues (1, 30, 31, 146, 150).  
 
Less well studied in human disease but also of interest is RASA1, a fellow member of 
the RasGAP family. RASA1 has been reported as the causative agent in the human 
disorder capillary malformation-arteriovenous malformation (CM-AVM), believed to 
be due to germline inheritance of one mutated Rasa1 allele followed by the loss of 
heterozygosity in the affected tissues (44, 206-210). CM-AVM is characterized by 
port-wine skin lesions in which developmental abnormalities result in arterial 
vasculature that is connected directly to venous vasculature (206). A number of 
RASA1 mutation-associated CM-AVM patients are afflicted with the disorder 
Parkes-Weber syndrome, in which large skin lesions are accompanied by 
subcutaneous arterialized veins and hypertrophy of the affected tissues (44, 211). In a 
minority of cases, chylothorax and chylous ascites, the pooling of lymphatic fluid in 
the thoracic or peritoneal cavities, were observed (44). 
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The generation of appropriate mouse models with which to study NF1 and RASA1 
deficiency has been challenging. Complete deletion of either RasGAP due to 
homozygous expression of null nf1 or rasa1 alleles has resulted in embryonic 
lethality (29-31). Recently, LoxP conditional knockout mouse models for nf1 and 
rasa1 have been reported. Systemic deletion of RASA1 in adult animals, by 
ubiquitously-expressed inducible Cre recombinase, has been shown to result in 
lymphatic vessel hyperplasia and leakage, culminating in the development of 
chylothorax and chylous ascites .This hyperplasia has been shown to be due to 
dysregulated Ras signaling downstream of the VEGFR3 on lymphatic endothelial 
cells (45). Systemic deletion of NF1 in adult mice and consequent myeloproliferative 
disorder has been described in one report (54); however, deletion of NF1 in specific 
tissues has shown that the loss of NF1 has similar effects in murine tissues to those 
observed in human tissues (1).  
 
In this report, we attempt to describe and understand the interactions between RASA1 
and NF1 in murine tissues by generating heterozygous or homozygous RASA1-
deficiency concurrently with homozygous NF1 deletion. We demonstrate that our 
model of systemic deletion of NF1 in adult mice results in the development of 
myeloproliferative disorder, similar to previous observations of systemic deletion of 
NF1 in all murine tissues as well as NF1-related human myelodysplastic syndrome. 
We show that rasa1 heterozygosity, previously reported to have no phenotypic effect 
in single-deletion mouse models, correlates with less predictable hematopoietic 
phenotypes when combined with NF1-deficiency. We further show that 
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homozygosity for both RASA1- and NF1-deficiency yields a further shift in 
hematopoietic disorders from myeloid leukemias, accompanied by a sharp increase in 
the development of thymic lymphoma, accompanied by activating Notch mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
4.3. Materials and methods 
 
Mice 
The generation of rasa1
fl/fl
 and nf1
fl/fl
 mice has been described previously (1, 212). 
Tamoxifen-inducible NF1-deficient, RASA1-NF1-double deficient, and RASA1-
heterozygous-NF1-deficient mice were generated by crossing rasa1
fl/fl
 and nf1
fl/fl
 mice 
with ubErt2Cre transgenic mice, which express Cre recombinase fused to a mutated 
estrogen receptor under the control of the ubiquitin promoter (213, 214). Floxed 
alleles were deleted in all tissues by the administration of tamoxifen on two 
subsequent days as previously described (212). Mice were 2-3 months of age at the 
time of injection. All mice are on a mixed C57BL/6 and 129 Sv background. 
C57BL/6 mice were purchased from JAX. All experiments were performed in 
compliance with University of Michigan guidelines and were approved by the 
University Committee on the Use and Care of Animals. 
 
Flow cytometry 
Single-cell suspensions of spleens, lymph nodes, thymuses and bone marrow as well 
as whole blood were depleted of red blood cells. Leukocytes were analyzed for 
surface expression of B220, TCR, Gr-1, CD11b, Ter119, CD4, CD8, CD44, and 
CD25 via staining with fluorochrome-labeled mAbs (BD Biosciences) followed by 
analysis on a FACSCanto (BD Biosciences) with FlowJo software (Treestar). 
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Histology 
Whole tissues were fixed in 10% formalin immediately following dissection. Five 
micrometer sections were stained with hematoxylin and eosin according to University 
of Michigan University Laboratory Animal Management Histology core protocols. 
 
Western blotting 
Thymocytes from rasa1
fl/fl
nf1
fl/fl
-ubErt2Cre mice, thymocytes and splenocytes from 
C57BL6 mice were lysed at a concentration of 2x10
7
 cells/ml prior to SDS-PAGE 
protein separation and western blotting. Normal and truncated Notch1 intracellular 
domain (NICD) was determined using a cleaved Notch-specific antibody (Cell 
Signaling).  
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4.4. Results 
 
Induced NF1-deficient mice present with myeloid leukemia 
 
As nf1 mutations are associated with myelodysplastic syndromes in both mice and 
men, we wished to determine if our inducible NF1-deficient mice would present with 
a similar phenotype. Following the administration of tamoxifen, we observed 
enlarged spleens in both observed nf1
fl/fl
-ubErt2Cre mice (Table 1). Flow cytometric 
analysis of the hematopoietic tissues of these animals revealed abnormally high 
frequencies of Gr-1
lo
CD11b
+
 and Gr-1
hi
CD11b
+
 cells in the spleens of both mice, 
with the highest frequencies observed in the older mouse (Fig. 34A). This 
corroborates earlier reports in which induced deletion of NF1 in adult mice resulted in 
overgrowth of myeloid cells in spleens (54). We also observed high frequencies of 
Gr-1
+
CD11b
+
 granulocytes in the bone marrow of both animals, and increased 
frequencies of CD11b
+
Gr-1
lo
 monocytes, especially in the older mouse (Fig. 34B). 
This also agrees with earlier reports of increased monocyte frequencies in induced 
NF1-deficient animals (54). We did not observe overt abnormalities in cardiovascular 
or neural function in either animal. 
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Table 1. Analysis of nf1
fl/fl
 –ubErt2Cre mice. 
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Figure 34. Myeloid leukemia in mice with induced systemic NF1-
deficiency..  
Shown are representative dot plots of live splenocytes (A) and bone marrow 
cells (B) from induced NF1-deficient and control mice that were analyzed for 
Gr-1 and CD11b expression. n = 2 mice. 
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Concurrent rasa1 heterozygosity and nf1 deletion yield mixed hematopoietic 
phenotypes 
Rasa1 heterozygosity has not previously been shown to induce abnormal phenotypes 
((29) and Lapinski, unpublished). To our knowledge, rasa1 heterozygosity has not 
been investigated concurrently with NF1 deletion. We generated rasa1
fl/+
nf1
fl/fl
 –
ubErt2Cre (RASA1 het) mice and induced deletion with tamoxifen. We expected 
development of myeloid leukemia, as we had observed in NF1-deficient mice, and in 
fact we observed this in 12 of 18 mice (Table 2).  
 
In the remaining mice, we observed phenotypes that were more difficult to classify, 
ranging from erythoid cell dysplasia to thymic lymphoma (Table 2). Further analysis 
of a mouse with a mixed phenotype showed histiocyte infiltration into the liver and 
spleen (Fig. 35A). Flow cytometric analysis revealed that the ratios of B and T cells 
were abnormal in the spleen, lymph nodes, and thymus (Fig. 35B). Analysis of the 
non-lymphocyte population in these tissues demonstrated that the ratios of Gr-
1
hi
CD11b
+
 granulocytes to Gr-1
lo
CD11b
+
 monocytes were also abnormal, with high 
frequencies of monocytes and few granulocytes (Fig. 35B) 
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Table 2. Analysis of rasa1
fl/+
nf1
fl/fl
 –ubErt2Cre mice. 
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Figure 35. NF1-deficient RASA1 heterozygous mice develop 
mixed/myeloid dysplastic syndromes..  
A, H&E sections demonstrating diffuse large-cell lymphoma, characterized by 
the infiltration of histiocytes. B,  top, abnormal B and T cell distributions are 
observed in a mouse with a mixed dysplastic syndrome. Bottom, abnormal 
CD11b expression in non-lymphoid cells. Data are representative of several 
experiments. 
117 
 
RASA1-NF1 double-deficient mice are predisposed to lymphoma development 
Next, we wished to investigate the effects of concomitant induced deletion of RASA1 
and NF1 in adult animals. Few studies have been conducted on the interactions 
between these proteins. We report here the first instance of double-deletion in adult 
animals. Double deletion of RASA1 and NF1 has been shown previously to result in 
a more severe embryonic phenotype than does either single deletion, although all are 
embryonic lethal (29). We considered the possibility that we might observe mice with 
phenotypic characteristics of both single deletions. 
 
Out of 14 mice observed, we categorized five with erythroid dysplasia, seven with 
non-myeloid dysplasia, and the remainder with various other disorders (Table 3). 
Curiously, only one mouse presented with chylothorax, the expected phenotype for a 
RASA1 single-deficient mouse. We have also observed that induced systemic single-
deletion of RASA1 in adult mice does not result in malignancy (unpublished 
observation). Further, only one case of myeloproliferative disorder, a common 
presentation in NF1 single-deficient mice, was observed. Clearly, concomitant double 
deletion did not result in a compounding of single-deletion phenotypes. 
 
The majority of mice showed abnormalities in a specific cell type. The mice that were 
classified as succumbing to erythroid dysplasia were so categorized due to 
abnormally high frequencies of Ter119
+
 cells. It is possible that erythroid dysplasia is 
due to dysregulated K-Ras signaling, which has been reported previously to be the 
major regulator in erythroid progenitor development (215), although we note that the 
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observations could have been due to the age of the mice. We did not investigate these 
cells further. 
 
Our initial observations of lymphoma in double-deficient mice were of grossly 
enlarged hematopoietic organs that resulted in abdominal swelling and/or labored 
breathing due to compression of the lungs and diaphragm (Fig. 36). H&E analysis of 
these organs showed massive infiltration of lymphocytes into the spleens and 
thymuses of double-deficient animals. We noted the complete loss of splenic red pulp 
as well as the loss of thymic architecture, as shown by a lack of demarcation between 
the cortex and medulla regions (Fig. 36). 
 
Using flow cytometry, we investigated the cellularity of the enlarged hematopoietic 
organs in double-deficient mice. We observed that there were abnormally low 
frequencies of the Gr-1
hi
CD11b
+
 and Gr-1
lo
CD11b
+
 granulocyte and monocyte 
populations in the spleens and bone marrow of double-deficient mice, indicating that 
abnormal proliferation in the myeloid compartment was not responsible for the 
malignancies (Fig. 37A). Further analysis of Gr-1/CD11b double-negative cells 
indicated abnormally low expression of B220 and TCR -chain on double-deficient 
cells, markers of mature B and T cells respectively, indicating the possibility of tumor 
cells with an immature phenotype (Fig. 37B). We noted that thymocytes from double-
deficient animals presented with abnormal expression of TCR, indicating that 
further investigation of the thymic compartment was required. 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Analysis of rasa1
fl/fl 
nf1
fl/fl
 –ubErt2Cre mice. 
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Figure 36. Lymphoma development in RASA1-NF1 double-deficient mice.  
Top, hematopoietic organs that had been removed from a control and double-
deficient mouse. Bottom, H&E-stained sections of spleen and thymus from the 
organs shown at top. Observe the loss of splenic red pulp and overall loss of 
thymic architecture in the double-deficient organs. Data are representative of 
multiple tumor-bearing mice. 
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Figure 37. RASA1-NF1 double-deficient mice develop non-myeloid 
lymphomas.  
Live cells from hematopoietic organs of double-deficient and control mice 
were analyzed by flow cytometry. A, Gr-1 and CD11b expression on live 
cells. B, B220 and TCR -chain expression on double-negative cells from (A). 
Data are representative of multiple experiments. 
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Characterization of thymic lymphoma resulting from RASA1-NF1 double-deletion 
We wished to characterize the malignancies we described in Figure 4.4. We were 
intrigued that, although we observed abnormally low frequencies of mature 
hematopoietic cell markers in the peripheral organs, we observed increased TCR 
expression in thymocytes (Fig. 37B). Analysis of hallmark thymocyte developmental 
subsets in double-deficient animals showed a large expansion of CD8
+
 cells with 
varying expression of CD4, indicating the development of thymic lymphoma (Fig. 
38A). We next wished to determine if the uncharacterized tumor cells observed in the 
periphery were in fact CD4
+
CD8
+
 cells of thymic origin. We analyzed CD8
+
 cells 
from peripheral hematopoietic tissues for CD4 expression and found that nearly all 
CD8
+ 
cells in the periphery also expressed high levels of CD4 (Fig. 38A).  
 
As we noted in Figure 37 that the tumor cells were largely TCR-negative, we further 
analyzed CD8
+ 
cells (which included CD4/CD8 double-positive cells) for TCR 
expression and found that all splenic tumor cells were TCR-negative, as were the 
majority of CD8
+
 cells in lymph nodes and blood (Fig. 38B). CD8
hi
 T-ALL 
thymocytes had been reported to express CD25 at high levels well past the DN3 stage 
of development, in which it is downregulated in normal thymocytes (20, 216). Using 
flow cytometry, we determined that nearly all CD8
+
 cells in the hematopoietic tissues 
of double-deficient mice expressed high levels of CD25 (Fig. 38B). Thus, the 
lymphoma cells that we observed were characteristic of previously described murine 
T-cell acute lymphoblastic leukemia/lymphoma (T-ALL). 
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Activating Notch1 mutations have been reported in more than half of human and 
mouse T-ALL cases, and are believed to act either as the causative agent or as an 
accelerant of disease (217).  In particular, up to 50% of murine T-ALL cases were 
found to possess truncating mutations in the Notch1 PEST domain, which normally 
facilitates protein degradation through ubiquitinylation (218). In mice, PEST domain 
mutations alone are not thought to be causative; however, murine T-ALL has been 
shown to present with RAG-mediated recombination events in Notch1 that result in 
the loss of the extracellular Notch1 domain, leaving the active intracellular domain 
(ICD) largely unchecked (219). Of particular interest to our work are reports that 
activating Notch1 mutations were found to be causative in multiple studies of murine 
T-ALL associated with expression of constitutively active KRas (23, 218, 220, 221). 
 
 To further confirm that the concomitant loss of RASA1 and NF1 expression was 
driving the development of T-ALL, we investigated the incidence of Notch1 
mutations in tumor cells isolated from double-deficient mice. Western blot analysis of 
thymocytes from the third thymic lymphoma case (Table 3) showed that the Notch1  
(ICD) band, expected at 100 kDa, appeared at a lower molecular weight than did the 
control sample, suggesting a truncating mutation (Fig. 39A). The increased density of 
the Notch1 ICD band in the lymphoma cell sample indicates increased protein 
expression (Fig. 39A). Sequence analysis of DNA from thymic lymphomas 
demonstrated activating Notch mutations in six of seven cases (Fig. 39B). The 
majority of mice expressed both  Type 1 mutations and PEST domain mutations, 
which prolong the activity of Notch ICD in the nucleus.  
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Figure 38. Double deficiency-associated lymphomas originate in the 
thymus.  
A, thymocytes were analyzed for developmental subsets using flow cytometry. 
Shown are representative CD4 vs. CD8 dotplots of total thymocytes. B, CD8+ 
cells from hematopoietic tissues were analyzed for the expression of CD4, 
TCR -chain, and CD25. Filled histograms represent control mice and dotted 
open histograms represent double-deficient mice. Data are representative of 
multiple experiments. 
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Figure 39. Activating Notch1 mutations in double-deficient thymic 
lymphomas.  
A, C57BL/6 control thymocytes and thymic lymphoma cells were analyzed for 
the presence of Notch1 ICD truncation via western blotting. At right are 
C57BL/6 splenocytes, which do not express detectable Notch1 ICD. B, 
graphical representation of activating Notch1 mutations associated with T-
ALL in double-deficient mice. N = 7 mice. 
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4.5. Discussion 
 
We have demonstrated that induced systemic deletion of NF1 in adult mice results in 
the development of myeloid dysplasia, similar to that which has been previously 
reported in murine models of NF1 deletion. We have also reported that heterozygous 
loss of RASA1 concurrently with deletion of NF1 results in less predictable 
hematopoietic phenotypes including myeloid dysplasia but also abnormal expansion 
of lymphoid and erythroid populations. Furthermore, we have shown that concurrent 
systemic deletion of RASA1 and NF1 in adult mice does not result in the 
development of diseases that are associated with either single deletion, but instead 
results in the development of thymic lymphomas with nearly 50% penetrance. 
 
Rasa1 has been shown previously to be haplosufficient in murine fetal development 
as well as somatic tissue function, although studies of the latter have been limited. For 
this reason, we were surprised that NF1-deficient mice with heterozygous expression 
of RASA1 did not simply recapitulate the NF1 single-deficient phenotype. Perhaps in 
the absence of one normal allele of rasa1, NF1 is able to substitute when Ras 
regulation is needed. Future studies will better illuminate the phenotypes that arise 
from heterozygous deletion of RASA1 concurrently with full deletion of NF1. 
 
Curiously, in our double-deficient mice, we observed very few instances of disorders 
that were characteristic of either single-deficient mice. For example, although 
chylothorax was commonly observed in RASA1-deficient mice, we observed only 
one such instance in double-deficient mice. Similarly, although NF1-deficiency has 
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been strongly associated with myeloproliferative disorders in our mice as well as in 
previously reported models, we observed only one clear instance of myeloid leukemia 
in double deficient mice. The reasons for this are unclear. We considered the 
possibility that perhaps disorders such as thymic lymphoma appear so quickly in 
double-deficient mice that other disorders are not afforded time to develop, but we 
noted that not all mice develop thymic lymphoma and those that do not develop 
lymphoma may survive for more than a year, by which time all RASA1 single-
deficient mice would have succumbed to chylothorax (45). The most likely 
explanation is that the simultaneous loss of two RasGAPs results in Ras-induced 
cellular senescence (222), although it is possible that effects resulting from each 
deletion are able to cancel out the effects of the other deletion. In future experiments, 
the interactions of these proteins to regulate hematopoietic cell development and 
homeostasis must be investigated further. 
 
We further consider that the lack of apparent cardiovascular and neural defects in our 
induced double-deficient adult mice is quite different from what was observed in 
homozygous RasGAP null-allele embryos. We did not closely investigate mice for 
abnormal vasculature or neural tissues, but other than sporadic hemangioma, we 
observed nothing overt beyond hematopoietic disorders. This could be attributed to 
unforeseen differences in response to RasGAP deletion between mouse and man. 
More likely, however, the timing of deletion relative to the age of the mouse is 
essential. RASA1 and NF1 may be less important to the maintenance of the blood 
vasculature network in adults, although they are critical for its development in utero. 
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The development of thymic lymphoma in some double-deficient mice is of much 
potential interest. Interestingly, although NF1 mutations are normally associated with 
myeloid leukemias in human patients, NF1 inactivation has been reported in the 
literature as a contributing mutation to T-ALL (157, 223). Notch mutations have also 
been reported to be a common feature in human and murine T-ALL (23, 157, 217). 
We described earlier that 6 of 7 double deficiency-associated thymic lymphomas 
possessed activating Notch1 mutations, similar to a previous report that a majority of 
human T-ALL have associated Notch1 mutations (224). Type 1 extracellular domain 
deletion mutations and PEST domain mutations have been described in murine T-
ALL associated with activating K-Ras mutations (20, 23), as have PEST domain 
mutations in human T-ALL (157, 224). We conclude that the acquisition of a Notch1 
mutation is the determining factor in the development of T-ALL in our double-
deficient mice, although the mechanisms by which this mutation is acquired and by 
which Notch1 signaling encourages the development of T-ALL have yet to be 
determined. We expect that this model may provide useful insight into the signaling 
events involved in Notch-mediated T-ALL. 
 
We also note that, although data have yet to be published, we did not observe 
abnormalities indicative of oncogenic Ras activity in mice that were RASA1-NF1 
double-deficient solely in the T cell compartment, due to transgenic expression of Cre 
under the control of a T cell-specific promoter. These mice had grossly normal 
thymocyte numbers and subset frequencies, as well as losses in peripheral T cell 
numbers similar to what we have previously observed in T cell-specific models of 
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RASA1 or NF1 single-deficiencies (unpublished observations). Our findings that a 
majority of mice with thymic lymphoma present with activating Notch1 mutations 
support the hypothesis that the timing of RASA1 and NF1 double-deletion, relative to 
T cell development, is critical. Further supporting this hypothesis is the understanding 
that regulation of Notch signaling is essential during early stages of T cell 
development. Loss of Notch1 signaling in thymic progenitors results in a loss of 
thymocytes and the expansion of B cell and myeloid populations (225-227). 
Conversely, overexpression of constitutively activated Notch1 in hematopoietic stem 
cells results in excessive T cell development (228). A better understanding of the 
relationship between the loss of these RasGAPs and the acquisition of Notch mutation 
is required. 
 
In conclusion, we have presented the first studies of systemic NF1 deletion and 
RASA1-NF1 double-deletion in adult mice. We have shown that NF1 single-deficient 
mice succumb to myeloid leukemia, while the additional loss of one RASA1 allele 
unexpectedly results in more mixed hematopoietic abnormalities. We have reported 
that nearly half of double-deficient mice develop T cell lymphomas that are 
phenotypically similar to human and mouse T-ALL. Finally, we have shown that 
more than half of double-deficient mice with T-ALL present with activating Notch 
mutations that likely accelerate disease. 
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Chapter 5 
 
 
Conclusion 
 
 
 
The experiments described thus far have increased our understanding of the 
regulation of homeostasis in the T cell compartment in mice, from development to 
effector function to suppression of oncogenesis. Throughout each part of this work, 
we have investigated the effects of regulations on TCR-activated signal transduction 
pathways. We believe that this research underscores the complexity involved in 
understanding how deletion of a single regulatory protein affects the development and 
maintenance of the T cell compartment. We have also demonstrated the complex 
interactions between signaling pathways downstream of the TCR and cytokine 
receptors and the influence of these interactions on T cell effector function, as well as 
the importance of timing on the deletion of RasGAPs and their roles as tumor 
suppressors in the T cell compartment. 
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NF1 as a regulator of T cell development 
Our studies of T cell-specific NF1 deletion at an early stage in thymocyte 
development led us to the conclusion that NF1 does have a moderate effect in the 
thymus. T cell-specific NF1 deletion, whether homozygous or heterozygous, results 
in a partial block in transition of cells through the DN stages of development. We 
found little evidence that other stages of thymocyte development were affected until 
we investigated clonal thymocytes in HY TCR-transgenic mice. Thymocytes in those 
mice appeared to have a partial block in the transition from the DP to CD8 SP 
developmental stages. We were unable to conduct studies of thymocyte development 
in mice that express a transgenic TCR that responds to peptide bound to MHC class II 
but expect that, in the future, such studies will yield further information on the role of 
NF1 in T cell development and CD4
+
 T cell function.  
 
Although we noted that NF1-deficiency negatively affects peripheral naïve T cell 
numbers, we were unable to determine the cause behind this phenomenon. NF1-
deficient T cells did not appear to be defective in IL-7-dependent survival, AICD, or 
proliferation. It is possible that NF1-deficient T cells may be hyporesponsive to 
another peripheral survival signal in vivo, leading to death by neglect. It is also 
possible that NF1-deficiency leads to increased activation of Ras and downstream 
signaling pathways, resulting in deletion of highly reactive cells as a means to 
maintain tolerance and lymphopenia-induced proliferation of remaining cells (74). 
 
We observed that NF1-deficient naïve CD8
+
 T cells were more potent effectors on a 
132 
 
per-cell basis when stimulated in vitro with CD3/CD28 mAb. However, we did not 
observe improved effector function when the cells were stimulated concurrently with 
IL-2 or IL-4, nor did we observe changes in the per-cell effector responses in CD4
+
 T 
cells. Upon cell activation, perhaps other RasGAPs are able to exert enough control 
over Ras signaling so as to maintain normal cell function in the CD4+ T cell 
compartment. It is also possible that our in vitro experiments are of limited 
physiological relevance. We did observe that T cell-specific NF1-deficient mice more 
efficiently responded to L. monocytogenes infection, so perhaps abnormalities in 
NF1-deficient T cells are more evident in an in vivo infection model. We note that 
pathogen-specific T cells would reside in the naïve cell compartments prior to 
infection, and that the increased effector capabilities observed in NF1-deficient naïve 
CD8+ T cells are likely responsible for the improved response to infection that we 
observed. However, we have not yet studied NF1-deficient T cells ex vivo after 
infection with L. monocytogenes to determine if numbers or frequencies of pathogen-
specific T cells are significantly different, or if increased effector function was 
evident upon restimulation. We have also not studied memory T cell responses in 
NF1-deficient mice in response to pathogen immunization and challenge. 
 
 
IL-4 as a promoter of CD8+ T cell effector function 
At first glance, IL-4 might seem to be the odd man out in this story. In fact, the IL-4 
experiments had their origins within our investigations into the role of NF1 in T cells. 
IL-4 caught our attention as, when used as a control for IL-2 in the in vitro activation 
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of CD8
+
 T cells, it broadly stimulated cells in both the NF1-deficient and control cells 
to produce very high amounts of IFN- Although IL-4 has been reported to promote 
CD8
+
 T cell effector functions, little attention had been paid to the specifics of the 
effector functions or the cellular mechanisms that drove them. 
 
We have shown that IL-4 is able to stimulate ifng gene expression de novo in CD8
+
 T 
cells via the upregulation of the transcription factors Eomes and T-bet, which we 
believe to be exciting and novel information that sheds new light on the abilities of 
cytokines to induce a variety of responses in different cell types. IL-4 has been long 
understood as the master cytokine behind the type 2 T helper cell (Th2) immune 
response and has thus been studied more widely in those cells. Canonical knowledge 
holds that, in Th2 cells, IL-4 signaling downregulates and even blocks IFN- 
expression. As CD8
+
 T cells that are differentiated under CTL type 2 skewing 
conditions also produce IL-4, it was expected that IL-4 induced similar gene 
activation and repression in CD8
+
 T cells as in CD4
+ 
T cells. We have clearly 
demonstrated that this is not so, and we expect that future studies will demonstrate 
IL-4-driven IFN- expression is the primary effector in models of infection that 
require IL-4 to promote efficient CTL responses and pathogen clearance. 
 
IL-4 had been reported in CD4
+
 T cells to activate the PI3K pathway as well as to 
promote the activation of the ERK MAPK (229). IL-4 was similarly reported to 
activate those pathways in previously stimulated CD8
+ 
T cells (193). It made sense to 
target those pathways in our in our studies. We observed that both PI3K and ERK 
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activation are required for the full induction of IL-4-mediated IFN- expression. We 
are uncertain of all the signaling events involved: certainly ERK and PI3K can be 
activated by Ras, and it is likely that further investigation would show induction of 
Ras signaling. We are also unsure of the mechanisms linking PI3K and ERK 
activation in IL-4-stimulated cells to the upregulation of Eomes and T-bet. One 
possibility is the activation of the mTOR pathway downstream of PI3K. mTOR 
signaling has been reported to enhance T-bet expression and repress Eomes 
expression downstream of the IL-12 receptor in CD8
+ 
T cells (116). Although 
preliminary experiments with Rictor-deficient CD8
+ 
T cells, in which the mTOR2 
pathway is inactivated, indicated that mTOR2 is most likely not a factor (data not 
shown), it is possible that the mTOR1 pathway may be modulated downstream of the 
IL-4 receptor.  
 
Although we have conducted a thorough analysis of the direct effects of IL-4 on IFN-
 expression in CD8+ T cells in vitro, we have yet to demonstrate the relevance of 
these findings in vivo. CD8
+
 T cells isolated from IL-4-deficient mice following 
inoculation with Schistosoma mansoni eggs and immune challenge with Schistosoma 
egg antigen failed to show a significant change in IFN- expression upon 
restimulation ex vivo, although moderate reductions were observed in Eomes 
expression (unpublished data). It is possible that the pathogen model used was not 
appropriate for CD8
+
 T cell studies, although it has been reported to induce Th2 
differentiation in vivo (230). Further, isolated CD8
+
 T cells from mice that had been 
previously infected with live schistosomes were found to express IFN- upon ex vivo 
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restimulation with antigen, although the mechanism behind this phenomenon was not 
explored (184). It is possible that IL-4-deficient mice are able to induce alternate 
responses in vivo to ensure appropriate immune responses against pathogens, thus 
masking the effects of IL-4 deficiency in our experiments.  
 
 
RASA1 and NF1 as tumor suppressors in the T cell lineage 
 
We are excited about the finding that concomitant systemic deletion of RASA1 and 
NF1 in adult animals can lead to the development of T-ALL, and that we observe 
Notch1 mutations in our murine T-ALL model at a similar frequency to that observed 
in human T-ALL (221). Although these data further our knowledge of RasGAP tumor 
suppressor activity in T cells as well as of factors that contribute to T-ALL initiation 
and severity, we are left with questions. 
 
First, what factor (or factors) initiates T-ALL in these mice? With one exception, we 
have only observed T-ALL development in mice that were double-deficient for 
RASA1 and NF1, and of those, fewer than half developed T-ALL. Although RASA1 
and NF1 are both known to regulate the activity of K-Ras, a known oncogene in T-
ALL (20, 23), clearly the loss of both RasGAPs is not enough to favor T-ALL 
tumorigenesis. As noted, activating Notch1 mutations were found in all but one of the 
T-ALL cases observed in double-deficient mice. We suspect that the T cell tumors 
that we have observed are clonal in nature; perhaps these cells derive from a single 
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mutated bone marrow progenitor. It would be of great interest to look at other 
transcription factors and signaling pathways that are known to be active and non-
redundant in thymocyte progenitor or early T cell development as perhaps one or 
more of these can also act as an oncogene. Constitutively activated Notch has been 
reported to bypass RAG-mediated recombination of the genes that code for the TCR, 
a crucial thymocyte developmental checkpoint, in RAG-deficient mice (231). 
Mutations in the DNA-binding transcriptional regulator Ikaros, which plays a non-
redundant role in thymocyte development, have also been reported in murine T-ALL 
along with activating Notch mutations (232, 233).  
 
Second, what mechanistic changes in signal transduction and regulation might 
account for the phenotypes observed in double-deficient mice, as opposed to those 
observed in single RasGAP-deficient mice? As noted in chapter 4, RASA1 is 
indispensable in the maintenance of lymphatic vasculature, while NF1 is essential as 
a tumor suppressor in the myeloid hematopoietic cell lineages; yet with few 
exceptions, we observe neither phenotype in double-deficient mice. A better 
understanding of the interactions between RasGAP proteins is required to explain this 
phenomenon. 
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